Lexaria Bioscience Corp. (NASDAQ: LEXX) Addressing Hypertensive Patients’ Concerns with DehydraTECH-CBD

September 29, 2022 09:05:00
  • Lexaria is a global innovator in drug delivery platforms whose lead technology is DehydraTECH(TM)
  • Studies have shown that DehydraTECH increases the intestinal bioabsorption of bioactive compounds by as much as 27 times, hence resulting in greater bioavailability; pre-clinical and human studies have demonstrated that DehydraTECH-CBD enables absorption increases of between 100% and 500% The studies have also shown that DehydraTECH-CBD results in a rapid and sustained drop in blood pressure among hypertension patients
  • Lexaria, which believes there is a significant unmet demand for cost-effective hypertensive treatments with few or no side effects, is working toward commercializing DehydraTECH-CBD to satisfy this demand

Currently, roughly 20% of people diagnosed with hypertension take medication, with the remaining majority noting that the medications’ side effects substantially outweigh the benefits. This has often constrained the fight against hypertension, the most common cardiovascular disease worldwide, which affects more than one billion people and is associated with long-term morbidities such as heart disease, stroke, and even death.

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, believes the hesitance or refusal to take medication presents a significant unmet demand for more tolerable, cost-effective anti-hypertensive treatments and has been working to bring such treatments to the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Provide Bioavailable Oral Treatment for Hypertension, Mitigate Effects of High Blood Pressure

September 21, 2022 08:05:00
  • Lexaria is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”)
  • The company has developed the patented DehydraTECH(TM) drug delivery technology, which has been shown to deliver more API at a faster rate than controls
  • Lexaria’s DehydraTECH pipeline includes DehydraTECH-CBD for the treatment of hypertension
  • Through pre-clinical studies, DehydraTECH-CBD has been shown to decrease systolic blood pressure among hypertensive volunteers
  • The company intends to file an Investigational New Drug (“IND”) application and has already received confirmation that the FDA agrees with its proposed abbreviated pathway under section 501(b)(2)

Oral delivery remains the preferred route of administering drugs among cooperating and conscious patients. But some drugs do not have the desired physicochemical and pharmacokinetic characteristics that favor oral administration, an issue that is linked to poor bioavailability. This has often led to the use of other routes or prompted the administration of higher doses, with the latter causing toxicity concerns and risks tied to erratic and unpredictable responses. These challenges, coupled with the fact that more than 90% of therapeutic compounds are known to possess oral bioavailability limitations, have necessitated research that explores ways to enhance oral drug bioavailability (https://cnw.fm/5fM38).

The research has been spearheaded by scholars and scientists as well as companies such as Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. A biotechnology company focusing its attention and resources on pursuing the enhancement of the bioavailability of a…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX), Growing its Market Share, One Patent at a Time

September 16, 2022 08:50:00
  • Lexaria’s development of its patented DehydraTECH(TM) technology since 2014 has yielded 27 patents in Australia, the United States, the European Union, Japan, India and Mexico with approximately 50 additional patents pending around the world
  • Its latest patent, granted in Mexico, applies a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a variety of ready-to-drink consumer retail beverage products
  • Lexaria remains committed to advancing its research and expanding the indications and efficacy of its DehydraTECH technology, as it looks to benefit from the CBD industry, projected to be valued at $111.8 billion by 2030, and the cardiovascular drugs market, projected to be valued at $107.8 billion by 2025

Since Lexaria Bioscience (NASDAQ: LEXX) began the development of its industry-leading DehydraTECH(TM) technology back in 2014, the company has remained steadfast in its goal to improve the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. Moreover, as a global innovator in drug delivery platforms, the company has not shied away from advancing its research to cut across various health conditions, including but not limited to hypertension, epilepsy, diabetes and dementia, among others.

These efforts have yielded 27 granted patents around the world since 2014, with approximately 50 additional patents pending. It also has national filings in over 40 jurisdictions with the highest commercial potential, reflecting the company’s commitment to creating shareholder value and pushing its…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Strengthens Board of Directors to Boost Efforts toward Regulatory Approval of Potential Treatment for Hypertension

September 14, 2022 08:05:00
  • Lexaria Bioscience is a global innovator in drug delivery platforms whose lead technology, DehydraTECH, has been shown to increase the bioavailability of APIs
  • The company recently announced that Catherine Turkel, PharmD, Ph.D., has joined its board of directors
  • Dr. Turkel, who brings over 20 years’ experience, has previously formulated Food and Drug Administration (“FDA”) registration and commercial strategic plans, as well as led global development programs for pharmaceutical and biologic treatments
  • Dr. Turkel will lend her drug registration experience and regulatory expertise to Lexaria at a time when the company is journeying toward regulatory approval for DehydraTECH-CBD, its drug candidate for the treatment of hypertension
  • Lexaria recently had a pre-IND meeting with the FDA, where it received positive feedback

Companies should bring on board members with strategic growth experience who have “been there, done that,” a June 2022 article in Forbes advises (https://cnw.fm/MUABF). Strategic growth, the article observes, “is one of the most important areas of governance for boards. The more experience on a board, the more efficient you are at developing tried and tested growth strategies… Members with experience down certain paths can guide a company to anticipate and avoid known obstacles, helping to accomplish goals faster.”

As Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, charts the long path toward regulatory approval for DehydraTECH(TM)-processed cannabidiol (“CBD”), a prospective treatment for hypertension, the importance of bringing on board members with…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Acquires 27th Worldwide Patent Applying to a Range of APIs in Ready-to-Drink Consumer Retail Beverage Products

September 12, 2022 08:05:00
  • Lexaria’s Mexican patent “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Ingredients” joins the ranks of previously issued patents in Australia, India, Japan and the EU
  • The patent allows the company to provide value in gaining regulatory approval for its DehydraTECH(TM)-enabled CBD for multiple indications in the health and wellness field
  • Additional claims to Mexican patent #390001 include Alzheimer’s disease, Parkinson’s disease, schizophrenia, Human Immunodeficiency Virus (“HIV”) dementia, obesity, hepatic diseases, diabetes, appetite disorders, cancer chemotherapy, benign prostatic hypertrophy, irritable bowel syndrome, biliary diseases, ovarian disorders, marijuana abuse, and alcohol, opioid, nicotine, or cocaine addictions
  • The global market of CBD for health and wellness purposes was valued at $4.9 billion in 2021 and is expected to grow to $47.22 billion by 2028

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that the Company has received its 27th worldwide patent, granted in Mexico under registration #390001. The patent from Lexaria’s third patent family, “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents,” has already been issued in Australia, India, and Japan (https://cnw.fm/bsY27). The patent applies to a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a wide variety of ready-to-drink consumer retail beverage products.

Lexaria’s latest patent provides value to the company through its continued pursuit of gaining regulatory approval for its patented DehydraTECH(TM)-enabled cannabidiol (“CBD”) for the treatment of hypertension in regulated pharmaceutical applications. This has produced the claims necessary for the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Quest to Find Hypertension Treatment Promising With DehydraTECH(TM)’s Ability to Boost Bioavailability

September 6, 2022 08:50:00
  • Lexaria, a global innovator of drug delivery platforms is looking to provide a FDA registered hypertension treatment with its patented DehydraTECH technology
  • The company’s efforts are encapsulated in its DehydraTECH-CBD that has been shown to lower blood pressure as well as reduce arterial stiffness
  • Although hypertension is a devastating condition that can cause not only life-threatening illnesses but also death, only about 53% of Americans with the condition have it under control
  • A Harvard Health article notes that the remaining portion (47%) are not able to control the disease because they are discouraged by medications’ side effects
  • Lexaria’s DehydraTECH-CBD may well be the solution such individuals seek, but for now, the company is following the regulatory pathway to eventual drug approval

Hypertension causes life-threatening conditions such as stroke, heart attacks, coronary artery disease, and heart failure. But even more concerning, the condition leads to death. In 2020, the U.S. Center for Disease Control (“CDC”) reported that high blood pressure claimed more than 670,000 lives in the U.S. (https://cnw.fm/1PKhk). Globally, hypertension claims an estimated 7.5 million lives annually, according to the World Health Organization (“WHO”) (https://cnw.fm/UCJeh).

Despite these devastating consequences and statistics, only about half (53%) of Americans living with high blood pressure have it under control, a problem that a Harvard Health article attributes to, among other common reasons, the fact that many stop taking their.

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces the Availability of a Broadcast titled, “The Power of Science to Stop a Killer”

August 30, 2022 08:50:00
  • Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this point
  • Since the company began developing its patented DehydraTECH(TM) technology in 2014, it has made significant progress in its clinical studies, even as it currently focuses on human clinical research to evaluate the tolerability, safety, and efficacy of its solution for hypertension treatment
  • Lexaria expressed its confidence in its proposed solution, noting that it will not only be a safer but also better-tolerated drug candidate, unlike current alternatives in the market whose side effects far outweigh their benefits
  • The company looks to capitalize on the growing global anti-hypertensive drugs market, which is projected to hit $27.81 billion in value by 2025, and maintains that should it sustain the results achieved in recent hypertension studies, then it could be looking at mega-drug status ($1 billion per year) in the hypertension market

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its latest addition to a growing body of corporate communication pieces in its line-up. Titled “The Power of Science to Stop a Killer,” this recent broadcast highlights the company’s progress in finding a potential solution for hypertension treatment, while also pointing out why a solution is much needed at this point (https://cnw.fm/6E6Dy).

Lexaria’s flagship offering, its patented DehydraTECH(TM) technology, has proven to improve ways through which active pharmaceutical ingredients (“APIs”) enter the bloodstream, primarily by promoting healthier oral ingestion methods and increasing the effectiveness of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program and Recent FDA Confirmation Position It for Favorable Valuation

August 26, 2022 10:20:00
  • Lexaria is a global innovator of drug delivery platforms, including its patented DehydraTECH(TM) technology
  • The company recently released information that would help its stakeholders research and understand how biotech and pharmaceutical companies are valued
  • Based on some of the methodologies used in valuation, Lexaria is positioned favorably as its DehydraTECH-processed CBD for the treatment of hypertension has successfully reached the IND application stage, with the program recently receiving an additional boost
  • The FDA agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, for its hypertension program

As a follow-up to recent coverage by Zacks Small-Cap Research, which valued the company at $15.00 (https://cnw.fm/obZ1e), global innovator Lexaria Bioscience (NASDAQ: LEXX) provided information to its stakeholders that would help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies.

“Valuation of equities is a complex task with innumerable risks and rewards that include far-reaching macro events as well as company-specific developments. It is nearly impossible to foresee all risks and rewards, but underlying logic-based evaluation is one way to provide a realistic framework of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Delighted About Well-Received DehydraTECH-CBD Proposals by the FDA; Maintains Late 2022/Early 2023 Target For Complete IND Application

August 19, 2022 08:50:00
  • Lexaria’s successful HYPER-H21-2 human clinical study, whose results were announced in the first week of September 2021, laid the groundwork for the company’s patented DehydraTECH(TM)-processed CBD NDA
  • Chris Bunka, the company’s CEO, referred to the results as “statistically significant,” ultimately kickstarting the IND application process with the FDA
  • Lexaria has since received a full written positive response from the FDA on its DehydraTECH-CBD, agreeing to the company’s proposal to pursue the 505(b)(2) NDA regulatory pathway
  • As a result of the favorable FDA response, Lexaria expects to remain on track to file its full IND application, 6-9 months sooner than if the FDA had required modifications in Lexaria’s current IND-enabling work plan, and Its management is confident that maintaining the current trajectory could allow the company to achieve $1 billion per year in the hypertension market, even making it one of the most effective registered pharmaceutical treatments for hypertension in the world

In the first week of September 2021, Lexaria Bioscience (NASDAQ: LEXX) announced its most recent results, at the time, from its HYPER-H21-2 human clinical study on the overall effectiveness of its patented DehydraTECH(TM)-processed CBD on blood pressure. The successful study would play an integral role in the company’s eventual New Drug Application (“NDA”), with Chris Bunka, the company’s Chief Executive Officer (“CEO”), terming the results as “statistically significant” (https://cnw.fm/X9wKM).

The success of multiple human studies investigating DehydraTECH-CBD for hypertension prompted Lexaria to formally announce the process of an Investigational New Drug (“IND”) application filing with the United States Food and Drug Administration (“FDA”) to list DehydraTECH-CBD as a…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Four Partnerships, Boosts ‘Revenue Picture’

August 16, 2022 08:05:00
  • Lexaria Bioscience, a global innovator in drug delivery platforms, recently announced partnerships with Premier Wellness Science Co., BevNology, AnodGen Bioceuticals, and Valcon Medical A/S
  • According to coverage by Zacks Small-Cap Research, who value Lexaria at $15 per share, the most impactful of these partnerships is with Premier because the company is expected to start paying license fees in early September
  • In a June 7 Fireside Chat, Lexaria Chair and CEO Chris Bunka disclosed that the company is capitalizing on partnerships with “national players in different areas of the world” to improve its “revenue picture” and offset its cash burn
  • In the longer term, the company is targeting milestone payments from large national and international consumer companies and pharmaceutical organizations

In a June 7 Fireside Chat hosted by John D. Vandermosten, CFA, of Zacks Small-Cap Research (“SCR”), Lexaria Bioscience (NASDAQ: LEXX) Chair and CEO Chris Bunka expressed hope that the then-ongoing negotiations with “national players in different areas of the world” would yield contracts that would significantly improve its revenue (https://ibn.fm/qhlo1). The negotiations led to separate announcements that form the basis of Zacks SCR’s latest coverage of the company, who value Lexaria at $15 per share (https://ibn.fm/OvOaJ).

“Lexaria experienced a substantial amount of activity on both the drug development front and in closing agreements with partners since the end of the fiscal second quarter,” Zacks notes in its coverage (https://ibn.fm/sGXzP). “The company announced four material partnerships in June that will provide…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to DehydraTECH-CBD FDA Evaluation Following Successful Dosing in Multi-Week HYPER-H21-4 Human Clinical Study

August 12, 2022 08:05:00
  • Lexaria just completed dosing for its HYPER H21-4 human clinical study that dosed 64 patients aged between 40 and 70 with measured elevated blood pressure, stage 1 and stage 2 hypertension
  • HYPER-H21-4, Lexaria’s most ambitious hypertension clinical study yet, builds on the success of HYPER-H21-1 and HYPER-H21-2, both completed in 2021
  • It explores the use of the company’s patented DehydraTECH(TM) technology in the potential treatment of hypertension
  • Lexaria is confident that the additional data sets collected over the course of the study will lead to supplementary applications for DehydraTECH while providing valuable additional insights into the long-term health benefits of this compound that might otherwise remain undetected

In November 2021, Lexaria Bioscience (NASDAQ: LEXX) announced its most ambitious hypertension study yet, HYPER-H21-4. The goal of the study, according to Lexaria’s Chief Executive Officer (“CEO”), Chris Bunka, was to “Support the company’s goals related to pursuit of regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure,” (https://cnw.fm/8fXrT). 

At the close of the year, Lexaria received independent Review Board (“IRB”) approval ahead of schedule, which marked a significant milestone for the company. It would set the stage for the commencement of the study in the year 2022 while allowing Lexaria to explore the full potential of its…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Generation of CBD Products Under “Ko” Branding by Japanese Licensee Premier Wellness Science Co., Ltd.

August 9, 2022 08:50:00
  • Lexaria’s patented DehydraTECH(TM) has 26 granted patents worldwide, including four in Japan
  • Lexaria stands to gain substantial revenue through the licensing of DehydraTECH technology across minimum quarterly payments for license use by Premier and royalties for products sold
  • By 2028, the CBD market is expected to reach US$47.22 billion, driven by increased demand for CBD use in health and wellness

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms and developer of the patented DehydraTECH(TM) technology for the delivery of fat-soluble molecules and drugs, has announced that Japanese Licensee, Premier Wellness Science Co., Ltd., has officially launched the first generation of its new cannabidiol (“CBD”) products under the brand, “Ko,” on July 21, 2022, for the Japanese consumer market (https://cnw.fm/Pm6hK). The exclusive rights between Premier and Lexaria are subject to two previously issued licenses for using DehydraTECH technology in Japan for non-pharmaceutical cannabinoid products. As of July 28, 2022, Lexaria has been granted 26 patents worldwide.

Under the terms of the license agreement with Lexaria, Premier purchased rights to the company’s DehydraTECH technology for use in the non-pharmaceutical market for CBD and hemp ingredients in oral liquid and non-liquid product forms, including topical, hair-care, lip-care, and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pending Start of Human Nicotine Study, NIC-H22-1, Leveraging Fast-Growing Global Nicotine Pouches Market

July 20, 2022 09:35:00
  • Lexaria Bioscience Corp. expects the upcoming human nicotine study to produce evidence that its patented DehydraTECH(TM) technology can enhance oral-tissue absorption with reduced negative experiences
  • Data collected from animal study NIC-A21-1 showed that DehydraTECH enhanced oral nicotine pouches delivered peak nicotine levels in the bloodstream of animals 10x to 20x faster than the control
  • The global nicotine pouches market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, being one of the fastest growing segments in the nicotine industry
  • Lexaria’s pipeline addresses serious unmet patient or consumer needs with greater market potential, addressing multiple mainstream applications in cannabinoids, oral nicotine, antiviral therapies, phosphodiesterase inhibitors, and other APIs

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the pending start of an upcoming human nicotine study, NIC-H22-1. The company expects to evidence that processing purified nicotine with its patented DehydraTECH(TM) technology leads to enhanced oral-tissue absorption and reduced negative experiences. NIC-H22-1 is a minimum 36-person human pharmacokinetic randomized, double-blind, cross-over study comparing DehydraTECH-nicotine pouch performance to existing brands currently on the market, including ON! and Zyn (https://cnw.fm/Dy3BE). 

The study’s primary objective is the objective data collection from blood samples that will evidence Tmax, Cmax, and AUC. Other study objectives include extensive subjective evaluations related to complaints of throat burn, user experience, and more. The nicotine test article ingredient manufacturing and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Best-In Class Solution To Major Issue Affecting A Range Of Critical Drug Applications

July 18, 2022 08:50:00
  • Researchers have run into the issue of solubility of molecules intended for absorption, ultimately affecting drug effectiveness and inhibiting patient recovery
  • This has forced the exploration of new drug delivery technologies, with Lexaria’s patented DehydraTECH(TM) technology proving to be the most innovative, useful, and effective
  • DehydraTECH(TM) technology has seen application in oral nicotine for reduced risk, antiviral drugs for COVID-19 and other infectious diseases, PDE5 inhibitors, and CBD for hypertension
  • The recent expansion of the Cannadips Brand into Europe, Japan, and South Africa highlights the proliferation of DehydraTECH and a significant growth in its market share, particularly in the CBD space
  • Lexaria is excited about the expansion and anticipates additional growth in its technology’s adoption as time progresses

For a long time, the medical industry has sought ways to improve patient health by enhancing the delivery of therapeutic drugs to target sites. An especially critical problem researchers in this sector have encountered is the limited solubility of the molecules intended for absorption. 

It is estimated that approximately 90% of preclinical drug candidates are low-solubility compounds. This presents a challenge regarding the compounds’ bioavailability and effectiveness of the drugs. The problem has led researchers to explore various drug delivery technologies, some of which have shown…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Licensee Expands Manufacturing Agreements to Include Europe, Japan, and South Africa

July 14, 2022 08:05:00
  • Lexaria’s patented DehydraTECH(TM) enhancement technology targets key market segments including nicotine replacement, CBD, cardiovascular and antiviral drugs, human hormones, and PDE5 inhibitors
  • DehydraTECH-enabled drug and consumer products provide faster delivery times, increased bioavailability, increased brain absorption, improved drug potency, lower administration costs, and mask unwanted tastes
  • The global CBD market was valued at $5.18 billion in 2021 and is expected to grow at a CAGR of 16.8% from 2022 to 2030, resulting in a revenue forecast of $22.05 billion by 2030

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that Boldt Runners Corporation, licensee of its patented DehydraTECH(TM) technology and owner of the Cannadips Brand, has expanded its manufacturing agreements to include Europe, Japan, and South Africa. Cannadips CBD dip pouches are the leading cannabidiol (“CBD”) pouch in the United States. They are a tobacco-free and nicotine-free dip alternative that provides an effective way for consumers to enjoy CBD. Cannadips is sold in over 6,500 retail locations across the United States, including direct-to-consumer online purchases (https://cnw.fm/x4P1h). 

Every tin of Cannadips product features DehydraTECH enhancement technology and results from longstanding collaboration and product design. “We are delighted with the expansion of the Cannadips brand outside of the USA. We continue to work with the Cannadips team on the infusion of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Enhances Bioavailability of Orally Administered APIs

July 12, 2022 09:35:00
  • Lexaria is a global innovator in drug delivery platforms
  • The company has developed the patented DehydraTECH(TM) technology that significantly improves the bioavailability of orally administered pharmaceuticals and therapeutics
  • Bioavailability is the fraction of a drug that reaches the site of action or systemic circulation
  • While drugs delivered intravenously are 100% bioavailable, drugs that have any other route of administration, such as oral, have reduced bioavailability
  • DehydraTECH enhances the bioavailability of APIs, in part, by bypassing first-pass liver processing

Global innovator Lexaria Bioscience (NASDAQ: LEXX) has built a reputation as a developer of drug delivery platforms, the most notable of which is the patented DehydraTECH(TM) technology. DehydraTECH is a formulation and dehydration processing method that modifies how the body detects and absorbs drugs, solving a glaring problem that has long affected orally administered drugs: low bioavailability. 

Bioavailability indicates the fraction or rate of the initial dose of a drug that is successfully made available to the site of action or systemic circulation (blood supply to all body tissues) from where target organs can readily access. “Intravenous dosing is considered 100% bioavailable since the drug is…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Production Capabilities to Support Growing List of Business-to-Business Clientele

July 6, 2022 09:35:00
  • Lexaria is a global innovator in drug delivery platforms; its patented DehydraTECH(TM) technology improves the bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“API”)
  • Testing confirms that DehydraTECH-processed cannabidiol beverages maintained 93.4% and 78% potency of CBD a full year and two years after production, respectively
  • Lexaria recently signed two agreements with BevNology LLC, an Atlanta-based company with advanced capabilities that support best-in-class beverage formulations
  • The partnership, which also leverages Lexaria’s superior DehydraTECH-CBD nanoemulsification formulation and processing techniques, could make industry-leading beverage products a reality for many brands 

In this year’s letter to shareholders, Lexaria Bioscience (NASDAQ: LEXX) Chair and CEO Chris Bunka acclaimed the company’s research and development achievements which had resulted in remarkable stability of DehydraTECH(TM)-processed cannabidiol (“CBD”) beverages. One year after production, Bunka wrote, “bottled consumer beverage contained a remarkable 93.4% potency of CBD. We also showed less than 1% variability of CBD potency within the beverage, a concept of critical importance when delivering drugs in an aqueous solution” (https://cnw.fm/H4ndc).

The latest data from stability testing undertaken 25 months after initial bottling show the product had higher variability but still retained an average 78% of originally formulated CBD. Additionally, the microbiologic purity and cleanliness of the product surpassed all requirements 25 months after…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CanadianCannabisWire is part of the InvestorBrandNetwork.

Flora Growth Corp.’s (NASDAQ: FLGC) Management Confident in the Company’s Short, Medium, and Long-Term Growth Prospects

July 5, 2022 10:20:00
  • Flora just announced the repurchase of $5 million of its outstanding common shares
  • This repurchase aligns with its overall global expansion plan, and its move to grow its market reach
  • These moves by Flora assure shareholders of the company’s commitment to driving shareholder value and exploring various opportunities to do so

On June 16, 2022, Flora Growth (NASDAQ: FLGC) announced that its Board of Directors had authorized the repurchase of up to $5 million of its outstanding common shares. This came in the wake of the expiration of a one-year lockup period for specific shareholders who had acquired shares before the company’s Initial Public Offering (“IPO”).

While making the announcement, Luis Merchan, Flora’s Chairman and Chief Executive Officer (“CEO”), noted…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Anticipates Continued Growth for Cannabis Operations Under New Colombian Administration

June 30, 2022 08:50:00
  • Flora Growth is a cannabis cultivator and distributor with a base of operations in Colombia’s fertile growing climate, capable of feeding the company’s expanding international supply chain
  • Colombia has undergone a number of regulatory changes in recent years as it emerges from the shadows of years-long drug wars and embraces a growing global acceptance of cannabis products
  • The South American country voted in a new presidential administration in June, and Flora Growth is applauding the president-elect’s continued openness to international cannabis trade
  • Flora Growth announced significant revenue growth during its year-end financial reporting in May, and the company stated it expects another 288 to 400 percent increase in revenues during the current year

Following nationwide elections that marked a historic change in Colombia’s presidency as well as its people’s social policy aspirations, emerging cannabis brand builder Flora Growth (NASDAQ: FLGC) is expressing optimism for its market opportunities, which are based on a growing cannabis cultivation operation in the South American country. 

Longtime legislator Gustavo Petro, a sitting senator and previously Mayor of Bogota, was declared Colombia’s chief executive-elect June 19 after his remaining opponent in a runoff election conceded that Petro had won the majority of the vote in an orderly transfer of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

New Agreements Signed Between Lexaria Bioscience Corp. (NASDAQ: LEXX) and BevNology LLC; Pre-IND Meeting Request Filed with FDA

June 29, 2022 10:20:00
  • The two companies signed a manufacturing operating agreement and a commercial agreement 
  • Lexaria sent a pre-IND meeting request letter to the US FDA and plans to file the full IND application in late 2022/early 2023
  • The FDA has acknowledged Lexaria’s pre-IND request and responded with conditions prior to the target date of July 30, 2022

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has recently announced signing two agreements with BevNology LLC, the product and development arm of InterContinental Beverage Capital (“IBC”), operating its state-of-the-art lab and manufacturing facility just outside of Atlanta, Georgia. This announcement only furthers Lexaria’s leverage of the market, with the company’s patented DehydraTECH(TM) technology having already been embraced by several consumer packaged goods brands, with availability in over 7,000 stores throughout the United States and Japan, including direct-to-consumer online retail portals (https://cnw.fm/Bjc3R).

The manufacturing operating agreement expands the production capabilities of Lexaria’s growing list of business-to-business clientele interested in purchasing DehydraTECH-powered active ingredients for packaged-goods brands. The new, state-of-the-art processing facility built by BevNology is…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Reach of its Drug Delivery Technology Through Newly Inked Agreements with Beverage Developer BevNology

June 27, 2022 09:35:00
  • Drug delivery technology innovator Lexaria Bioscience has developed a patented technology showing superiority in animal and human testing as a means of improving existing drug brands’ performance and establishing new solutions for unmet medical needs
  • The company recently announced agreements with beverage developer BevNology to expand production capabilities for Lexaria’s own growing list of B2B clientele and empowering BevNology to offer DehydraTECH products with active ingredients derived from hemp including CBD under BevNology and partnered brands 
  • The technology is called DehydraTECH — improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery  
  • Lexaria also recently announced an agreement with Ireland’s Anodgen Bioceuticals that allows Anodgen to manufacture and distribute DehydraTECH processed cannabinoid API powders within Europe including the UK, Australia and New Zealand

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has built the reputation of its patented DehydraTECH drug delivery technology through a growing data set of potential medicinal applications and through an expanding list of licensing agreements with third-party companies interested in its potential for cannabidiol (“CBD”)-based products. 

Lexaria’s patented DehydraTECH technology transforms a wide variety of orally and topically administered products into enhanced solutions that make the APIs more rapidly available and effective at…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants Licenses to Three Companies for the Month of June; Looks to Follow Through with its Scheduled 2022 Clinical Studies

June 23, 2022 08:05:00
  • Lexaria sold Premier Wellness Science Co. exclusive rights to use its patented DehyraTECH(TM) in Japan in a variety of CBD products
  • Valcon Medical A/S also signed an agreement with Lexaria to use its platform for medical cannabis applications in Europe
  • AnodGen Bioceuticals received a pharmaceutical license to use the platform for manufacturing and distributing CBD API powders in Europe, Australia, and New Zealand

Lexaria Bioscience (NASDAQ: LEXX) kicked off the month by announcing an exclusive license to Premier Wellness Science Co. for the use of its patented DehydraTECH(TM) technology in Japan in a variety of CBD products. Announced on June 3, this license would cover oral or non-liquid products and can be used in topical, hair-care, lip-care, and cosmetics segments. 

Premier is a wholesale and retail marketer of cosmetics and health foods in Japan. It also provides information and consulting services to entities in the anti-aging, beauty, and health industries. In addition, Premier also offers market research, data collection, and analysis for its…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Expanding Array of API Enhancements Through Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented Drug Technology Bodes Well for New Patient Solutions

June 21, 2022 08:50:00
  • Drug bioavailability enhancement technology developer Lexaria Bioscience is working to increase the number of potential new solutions to unmet medical needs and improving existing treatments for other chronic conditions
  • Lexaria’s patented DehydraTECH solution transforms a wide variety of orally and topically administered products into enhanced solutions that make the active pharmaceutical ingredients (“APIs”) more rapidly available and effective at lower doses 
  • DehydraTECH-enhanced products have also demonstrated the ability to cross the blood-brain barrier through fatty acid transport proteins 
  • The company’s ongoing series of tests of different DehydraTECH-enhanced products has led to a pre-IND filing with the FDA for a prospective registered treatment for hypertension, while other anticipated potential therapies target seizures, nicotine addiction and erectile dysfunction

The COVID pandemic that roiled the world’s healthcare systems during the past two years (and appears to be hospitalizing an increasing number of patients again (https://cnw.fm/iEIXl) revealed a marked demand for repurposing existing drugs for unanticipated treatments, particularly prior to the provisional development of various targeted vaccines to combat the novel coronavirus (https://cnw.fm/cnOfh). 

New data analysis has revealed the potential for several existing biopharma products to be repositioned to treat patients with unmet medical needs, potentially opening the way for dozens of new solutions to…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Achieves Key Milestone in Global Expansion Plan with JustCBD Launch on Amazon UK

June 17, 2022 08:05:00
  • Flora Growth completed the acquisition of Just Brands LLC and High Roller Private Label LLC, owners of the JustCBD brand, on February 28, 2022
  • The company then expanded its operational footprint in Europe and the UK in May 2022 to further its international growth strategy
  • JustCBD products, including gummies and tinctures, will be available on www.Amazon.co.uk starting this month in a pilot-only program
  • Flora Growth is optimistic that this launch will allow the company to reach a larger consumer base as it works towards further expanding its operations across Europe

On February 28, 2022, Flora Growth (NASDAQ: FLGC) completed the acquisition of 100% equity interests of Just Brands LLC and High Roller Private Label LLC, owners of the JustCBD brand. The transaction, which involved a consideration of $16 million in cash and 9.5 million in privately issued Flora common shares, was a move by Flora Growth to explore global expansion opportunities and increase the company’s customer database (https://cnw.fm/ccydT).

By mid-May 2022, Flora Growth had already announced the expansion of its operational footprint in Europe and the United Kingdom to further its international growth strategy. But, more importantly, the move signaled the company’s assertive push to broaden the reach for its JustCBD’s…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Initiates Communication with the FDA Concerning Potential Treatment for Hypertension; Out-Licenses Its DehydraTECH Technology to International Markets

June 15, 2022 09:35:00
  • Lexaria, a global innovator of drug delivery platforms, recently filed a pre-IND meeting request letter with the FDA, initiating communication regarding the development of its DehydraTECH-CBD as a treatment for hypertension
  • The company has been undertaking preparatory programs in readiness for the meeting, as well as an IND application filing
  • The pre-IND meeting will confirm the details of the company’s IND-enabling program
  • Lexaria also announced it had licensed its DehydraTECH technology to AnodGen, with the announcement following similar out-licensing agreements with Valcon Medical and Premier Science

Early last September, global innovator Lexaria Bioscience (NASDAQ: LEXX) was pleased to announce it had formally commenced the process toward an Investigational New Drug (“IND”) application filing with the Food and Drug Administration (“FDA”) with its DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of hypertension (https://cnw.fm/rDcfI).

According to the September 8 news release, Lexaria had retained the services of an expert regulatory affairs and quality assurance consulting group that would help prepare the company for a pre-IND meeting with the FDA. The group would also assist Lexaria with designing the requisite…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Adding to Cannabis Product Line, Research

June 8, 2022 08:50:00
  • Flora Growth is building on its cannabis brand globalization efforts with two partnerships that expand its product portfolio and its research efforts in the United States and United Kingdom
  • Flora’s partnership with former NFL athlete Ricky Williams has delivered its first product — a cannabis one-hitter accessory designed to provide a unique experience emblematic of Williams’ active lifestyle brand
  • The company’s acquisition of the Masaya CBD brand developed by a cell biologist on Flora’s board of directors gives the company a formulation suitable for its current clinical trial efforts in the United Kingdom, and a well-received brand designed to help seizure patients
  • Flora’s cultivation operations are centered at its Colombia facility, and recent regulatory changes there have made it easier for Flora to supply its brands in the United States and elsewhere

On the heels of a year in which global cannabis market brand-builder Flora Growth (NASDAQ: FLGC) saw rapid expansion of its cultivation, manufacturing and distribution operations that support the company’s business divisions for cosmetics, hemp textiles and food and beverage products, Flora is increasing its offerings by bringing a promising  CBD brand into its fold and introducing a new product for quality cannabis experiences. 

The acquisition of cell biologist Dr. Annabelle Manalo-Morgan’s Masaya brand gives Flora Growth its first offering under its Flora Life Sciences division as well as a patent-pending formulation for use in Flora’s…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Mines Potential of Helping Medicines Do What they Do, But Better

June 3, 2022 08:05:00
  • Lexaria Bioscience is a global innovator in drug delivery platforms, developing a technology designed to improve the performance of other medicinal products by making them more rapidly and effectively usable by patients’ bodies
  • Lexaria’s patented DehydraTECH technology has been studied in combination with a number of other products, including but not limited to, cannabidiol (“CBD”), oral nicotine, antivirals, NSAIDs, and erectile dysfunction therapies
  • The company is pursuing FDA approval under the Investigational New Drug (“IND”) process to clinically test its DehydraTECH-CBD for the treatment of high blood pressure
  • A driving focus of the company’s R&D has been to improve the speed of onset, increase bioavailability and brain absorption of active pharmaceutical ingredients

A common refrain in the world of advertising medicinal substances is that a select product can enhance a patient’s ability to live an active life despite debilitating medical conditions. 

“By helping to control eczema with Dupixent you can show more (skin),” one prominent ad message declared in recent months, while another offered examples of hope by testifying, “Opdivo plus Yervoy…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Consistently Enhancing the Oral Administration of Active Pharmaceutical Ingredients

June 1, 2022 08:05:00
  • A global innovator in drug delivery platforms, Lexaria has developed a patented technology, DehydraTECH(TM) 
  • Through research, Lexaria has evidenced that DehydraTECH enhances the efficiency and speed of orally- administered fat-soluble active pharmaceutical ingredients (“APIs”)
  • Lexaria is consistently enhancing the delivery of APIs that affect current oral formulations: speed of onset, limited absorption, and low membrane permeability
  • Lexaria has conducted numerous ground-breaking studies, some of which open up the possibility of fast-acting oral products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking

Oral formulations account for approximately 90% of the global share of all pharmaceutical formulations made for human use. Statistics also show that about 60% of all established, commercially available small-molecule drug products today and approximately 84% of all best-selling pharmaceutical products are orally administered. Oral drug administration is preferred because it offers numerous advantages over other delivery methods (for instance, intramuscular, subcutaneous, intravenous, and inhalation), not the least of which is high compliance of patients. Additionally, the drugs can be used to offer localized treatment of affected regions within the gastrointestinal tract.

“Despite these advantages, the development of oral formulations presents several challenges, which are mainly attributed to the physicochemical properties of drugs, including poor water solubility and membrane permeability. In addition, the absorption of drugs can be limited by their poor chemical and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging Growing Commercial Opportunities

May 27, 2022 08:05:00
  • Lexaria is a biotechnology company focused on licensing its proprietary DehydraTECH(TM) technology
  • The DehydraTECH technology has been proven to increase the bioavailability, speed of onset and brain absorption of APIs, and improve customer experiences by masking unwanted tastes
  • Lexaria has 25 patents granted worldwide and is pursuing numerous other pending patent applications
  • The company operates several subsidiary companies to focus on different commercial opportunities 

Ever since acquiring its first intellectual property (“IP”) that subsequently formed the basis of its first two patent application filings in 2014, biotechnology company Lexaria Bioscience (NASDAQ: LEXX) has grown the number of patents granted and patent applications exponentially, with 25 patents granted worldwide as of April 2022. The latest patent, the 10th granted in the United States, represents the first-ever patent for the use of DehydraTECH(TM) drug delivery technology in the enhanced delivery of antiviral drugs. Described by CEO Chris Bunka as “another validation of the versatility of our DehydraTECH drug technology,” the award of the IP protection marks a key step toward the ultimate monetization of DehydraTECH, according to an April 21 news release (https://cnw.fm/q8zmr).

This monetization, Lexaria’s annual report (Form 10-K filing) for the fiscal year ended August 2021 notes (https://cnw.fm/bCzFD), will be realized through the company’s focus on R&D and subsequent strategic…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Year-end Report Shows Significant Revenue and Profit Growth, with Expectations for Further Rapid Growth in 2022

May 23, 2022 08:05:00
  • Cannabis cultivator and distributor Flora Growth has announced its annual financial and operating results, showing “significantly higher” revenues and profit gain for 2021 over the previous year
  • Flora maintains an outlook for 2022 of an additional 288 to 400 percent revenue growth by year end, largely driven by the company’s acquisition of consumer wellness brand JustCBD
  • The JustCBD acquisition increased Flora’s reach to more than half a million consumers through 14,000 retail stores in the United States
  • Flora’s operations are centered at its Cosechemos cultivation facility in central Colombia, where the company enjoys ideal growing conditions year-round and has easy access to an experienced labor force
  • The company recently announced the appointment of industry veteran Holly Bell as Vice President of Regulatory Affairs to help guide the company’s expansion strategy throughout the United States and internationally

Cannabis cultivator and brand builder Flora Growth (NASDAQ: FLGC) spent 2021 establishing the company footprint as a global market distributor and on May 10 announced financial and operating results for the fiscal year that show the success of its efforts as revenues and profits begin what is expected to be rapid climb. 

Flora Growth’s financial growth arises from operations based in Colombia’s prime growth conditions heartland, the nation’s new regulatory openness to cannabis product exports for health and wellness…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Influencing the Pharmaceutical Industry

May 11, 2022 08:00:00
  • Lexaria began its human clinical study on oral nicotine alternatives, evaluating the effectiveness of its DehydraTECH-nicotine pouch performance 
  • Earlier in the year, the company also announced the commencement of its HYPER-H21-4 human clinical study on the effectiveness of DehydraTECH-processed CBD for hypertension treatment
  • Lexaria has also made some significant progress in the use of its technology for the enhanced delivery of antiviral drugs
  • It hopes that before the end of 2022, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation

Lexaria Bioscience (NASDAQ: LEXX), since its inception, has been pushing the boundaries of drug delivery. Through its patented technology, DehydraTECH(TM), the company has achieved more efficient delivery of active pharmaceutical ingredients into the bloodstream while also increasing their bioavailability.

Its technology has seen application in pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspensions. Lexaria has explored its usage in the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Update on its Patented DehydraTECH(TM) Technology, Including the Approval of New Patent

May 3, 2022 09:05:00
  • Lexaria received its 25th patent – and the first patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs
  • The company is seeking IND approval from the FDA and has commenced its human HYPER-H21-4 study for hypertension with DehydraTECH-CBD, with results expected in Q3 2022
  • Lexaria is also commencing its human oral nicotine study, NIC-H22-1 to compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the US such as ON! and Zyn

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced some positive news that further promotes the company’s goal of creating innovative drug delivery alternatives with its proprietary patented DehydraTECH(TM) technology. Lexaria is making the delivery of drugs quicker, more efficient, and even tasting better.

The company was granted its 25th patent – the first received for the use of its DehydraTECH technology for the enhanced delivery of antiviral drugs. The official word was received from the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands its Patent Portfolio With New Patent for Antiviral Drug Delivery with DehydraTECH

April 29, 2022 09:05:00
  • Lexaria just received another patent for DehydraTECH(TM): this time for the enhanced delivery of antiviral drugs
  • This becomes the company’s 25th patent granted worldwide and the 10th granted in the U.S.
  • It adds to the company’s growing patent portfolio, which also consists of ~50 pending patents worldwide
  • Over the 2022 calendar year, the company seeks to also pursue regulatory and commercial advancement

In 2016, Lexaria Bioscience (NASDAQ: LEXX) received its first United States patent grant and over the years, the company has been aggressive at broadening its patent suite, a move which it has attributed to refining the patent claims via further US provisional and utility patent filings. More patents mean more intellectual property and enhanced ability to pursue regulatory and commercial progress.

As of March 2022, Lexaria had 24 patents, having been granted its latest one in Australia, titled…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Fourth Human Study for Reducing Hypertension, Reports Positive Outcome of Third Human Study’s Data

April 27, 2022 09:05:00
  • Global drug delivery innovator Lexaria Bioscience is researching the ability of its patented DehydraTECH(TM) technology to improve the performance of a number of prescription drugs 
  • Lexaria is a world leader in the investigation of a DehydraTECH-processed cannabidiol (“CBD”) to potentially treat high blood pressure (hypertension), and study outcomes thus far have rendered positive results on effectiveness and patient tolerance
  • The company is building a scorecard of data to support its planned FDA application for formal, registered clinical testing under the Investigational New Drug (“IND”) process
  • Lexaria recently completed all data analyses of its HYPER-H21-3 study examining DehydraTECH-CBD’s ability to reduce pulmonary artery systolic pressure, and launched HYPER-H21-4 to gather a variety of data points related to DehydraTECH-CBD’s use over a more extensive period of time

High blood pressure has long been labeled “the silent killer” because of its propensity to lead to incapacitating or prematurely deadly strokes, heart attacks and other serious disease indications without necessarily foreshadowing pain or great discomfort. According to the World Health Organization (“WHO”), an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension but only about 1 in 5 (21 percent) people with the condition have it under control with medical treatment (https://cnw.fm/jDeE3). 

During the past decade within the United States, about 49 percent of the population reported taking at least one prescription medication in the past 30 days in data sampling collected by the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text “CCWIRE” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CanadianCannabisWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX): A Review of Its Research Developments

April 12, 2022 09:20:00
  • Lexaria Bioscience, the global innovator behind DehydraTECH drug delivery technology, has continuously focused on research into its patented technology
  • The company has conducted both in vitro testing and in vivo animal and human testing to evaluate the ability of DehydraTECH to improve the delivery of various APIs (active pharmaceutical ingredients)
  • Lexaria has multiple other studies lined up aimed at building sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation

As it moves toward national and international implementation and commercialization of its patented DehydraTECH(TM) drug delivery technology, Lexaria Bioscience (NASDAQ: LEXX) is aware of the need to continuously advance its understanding of the technology’s capabilities and potential applications. This informs the company’s long-held commitment to its applied research and development (“R&D”) programs, which are exclusively designed to “reduce future risks of both commercial and regulatory failure by identifying weaknesses as early as possible; and to enhance the likelihood of future commercial and regulatory success by thoroughly understanding strengths and weaknesses, also as early as possible” (https://cnw.fm/vY9V1).

Lexaria’s DehydraTECH technology combines a lipophilic active pharmaceutical ingredient (“API”) with a carrier particle, then it is dehydrated and finally rendered as a liquid or powder. Through the years, Lexaria has proven that DehydraTECH results in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

To receive instant SMS alerts, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals Inc. (NASDAQ: INM) Gaining Advantage on Processing Rare Cannabinoids with the Help of Subsidiary Bay Medica

April 12, 2022 09:20:00
  • There is an urgent need for large-scale biosynthetic processing that preserves the purity and consistency of cannabinoids
  • Acquired by InMed in October 2021, Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector
  • InMed has two cannabinol formulations currently in development for ocular and dermatological diseases – INM-088 (ocular for glaucoma) and INM-755 (dermatological cream for epidermolysis bullosa)

The global cannabis market increased exponentially after the pandemic hit, and is anticipated to continue its upward trend over the next few years. The market was valued at $20.47 billion in 2020, reporting a growth rate of 50.92% that year. The sector reached $28.66 billion in 2021 and is anticipated to hit $197.74 billion in 2028, expanding at a CAGR of 32.04% (https://cnw.fm/YYtTc). The market growth is paired with an increased demand for rare cannabinoids, with research showing that the biosynthesis of rare cannabinoids is projected to reach $25 billion in 2025 and up to $40 billion by 2040 (https://cnw.fm/B7SRh).

The problem faced by companies looking to work with rare cannabinoids on an industrial scale is the lack of efficient biosynthetic production methods that can ensure purity and consistency at high levels of production. Many companies find small-scale processing efficient for maintaining purity and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

To receive instant SMS alerts, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Multiple Strong Market Paths

April 6, 2022 09:05:00
  • Lexaria is a global innovator that has developed the patented DehydraTECH(TM) technology that improves bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”)
  • The company strategically partners with third-party organizations seeking to explore formulation opportunities with their specific APIs
  • Lexaria is evaluating the effectiveness of various DehydraTECH-processed APIs, including CBD, nicotine, sildenafil, and more
  • According to company CEO Chris Bunka, the management team is positioning the company to ensure that it has multiple paths to success

In pursuit of multiple paths to success, Lexaria Bioscience (NASDAQ: LEXX), developer of the patented DehydraTECH(TM) drug delivery platform, strategically partners with third-party companies looking to explore formulation opportunities with their targeted APIs, out-licenses its technology, and is actively developing lead product candidates. According to a 2021 video, the company also hopes to provide a lifeline to pharmaceutical companies noting that DehydraTECH(TM) “may provide additional patent extensions for existing drugs, which is a potential billion-dollar insurance policy to original drug manufacturers” (https://cnw.fm/6OXrO).

So named because it features a dehydration synthesis procedure, the DehydraTECH technology has been found to improve bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”). To discover more about the effectiveness of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals Inc. (NASDAQ: INM) Increasing Rare Cannabidiol Product Portfolio, Revenues

April 6, 2022 09:05:00
  • InMed Pharmaceuticals is a Canadian clinical-stage drug development company focused on the development of rare cannabinoids and their synthetic counterpoints for B2B sales and pharmaceutical potential
  • InMed expects to have rare cannabinoids CBDV and THCV available for B2B sale to the health and wellness market in the coming months, following on the heels of its CBC and CBT products
  • The company recently reported its first revenues from CBC sales in the wake of its acquisition of rare cannabinoids manufacturer BayMedica late last year
  • The company is also working to develop synthetic CBN cannabinoids as potential medical treatments for select conditions, including glaucoma and a severe genetic skin disorder known as epidermolysis bullosa (“EB”)

Rare cannabinoid drug developer InMed Pharmaceuticals (NASDAQ: INM) is expanding its product manufacturing scale, thanks largely to the acquisition of consumer-focused rare cannabinoids manufacturer BayMedica last year to better approach the pharmaceutical and health and wellness markets (https://cnw.fm/9lVDp). 

InMed’s most-recent Q2 financial statement reported revenues of $0.3 million from commercial sales of cannabichromene (“CBC”) to the health and wellness market following the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Continues to Showcase Ability to Improve Effectiveness of Existing Drug Brands

April 1, 2022 09:05:00
  • Health and wellness drug product innovator Lexaria Bioscience has developed a patented technology — DehydraTECH (TM) — which enhances the bioavailability of fat-soluble drugs and molecules
  • Lexaria continues to research DehydraTECH’s ability to improve the speed and bioavailability of cannabidiol (“CBD”) in treating high blood pressure and epileptic conditions
  • The company continues its research demonstrating the ability of its technology -to enhance the performance of antiviral drugs and other active pharmaceutical ingredients
  • Sublicensing DehydraTECH continues to create revenues for the company
  • Lexaria has additionally pursued the use of its drug-enhancing technology, in partnership with sublicensees, for making adult-use recreational cannabis more effective

The potential for drug innovator Lexaria Bioscience’s (NASDAQ: LEXX) patented DehydraTECH(TM) technology to transform the pharmaceutical industry continues to display itself in clinical trials and licensing deals that advance use and awareness of the technology.

The company recently announced it has begun animal research to compare effectiveness of FDA-approved Epidiolex to DehydraTECH-CBD for reducing seizure activity. Epidiolex, the world’s…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Reaches Agreements Green-Lighting High-THC Cannabis Exports from Colombia, and Outlets for Premium CBD Skin Care Product in Asia

March 25, 2022 09:35:00
  • Cannabis product cultivator Flora Growth Corp. operates a premium growing facility in central Colombia and has received a growing list of authorizations to export its cannabis products for varied health and wellness purposes
  • Flora Growth’s authorized distribution of low-THC CBD cannabis derivatives has been recently expanded to include a quota of up to 43,600 kg of products with high-THC cannabis
  • Flora also reached agreement with Israel-based DNO Group to further commercialize Flora’s Mind Naturals skin care products through potential distribution outlets in Hong Kong, with plans to build into outlets in Israel and India later
  • Colombia has also authorized the company to add four new genetic strains to its high-yield THC and high-yield CBD (cannabidiol) product portfolio for use in commercial products

Global cannabis brand builder Flora Growth (NASDAQ: FLGC) solidified distribution deals this month that expand the amount of high-THC (tetrahydrocannabinol) dry flower and cannabis derivative products it is permitted to export from its Colombia base of operations and open new market opportunities for its Mind Naturals skin care products in Asia and Eastern Europe.

Flora Growth is an internationally focused company with all-outdoor cultivation facilities in central Colombia where growing conditions are some of the most ideal in the world. Its 100-hectare (about 247-acre) Cosechemos facility benefits from a government that…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Phase of Epilepsy Research Using DehydraTECH(TM)-CBD

March 22, 2022 09:05:00
  • Lexaria’s patented DehydraTECH(TM) technology provides faster delivery times, increases bioavailability, increases brain absorption, improves drug potency, reduces administration costs, and masks unwanted flavors
  • The epilepsy research will compare the FDA-approved Epidiolex(R) to the company’s proprietary DehydraTECH-CBD formulation
  • The global cannabidiol (“CBD”) market had an estimated value of $2.7 billion in 2021 and is expected to reach $111.8 billion by 2030, driven by an increase in demand for CBD use in health and wellness industries

Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW), a global innovator in drug delivery platforms, recently announced that the first phase of its epilepsy research program, EPIL-A21-1, has begun. The research program will assess the seizure-inhibiting activity of cannabidiol (“CBD”) administered via the company’s proprietary DehydraTECH(TM) technology, compared to the only FDA-approved CBD-based seizure medication, Epidiolex(R) (https://cnw.fm/tNlxG). Epidiolex(R) is the first and only FDA CBD medication for the treatment of seizures associated with two rare forms of pediatric epilepsy — Lennox-Gastaut syndrome and Dravet syndrome.

Using DehydraTECH’s advanced drug delivery capabilities, Lexaria hopes to demonstrate superior performance in the research program. The company expects to achieve significant gains in systemic delivery and brain uptake — which have been…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Intellectual Property Portfolio Grows Following Receipt of 24th Granted Patent

March 21, 2022 09:20:00
  • Lexaria has received a new patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof”
  • The new patent, granted in Australia, is the first awarded from Lexaria’s 8th patent family and offers IP protection across a total of 9 claims
  • Lexaria believes the patent could be meaningful as it seeks to build value
  • With the new patent, Lexaria’s IP portfolio has now grown to 24 granted patents worldwide

In his letter to shareholders dated January 27, 2022, Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka documented the company’s expectation that it would receive additional patents in 2022. The expected patents would build on the company’s already solid intellectual property (“IP”) portfolio that expanded severalfold last year when Lexaria was awarded five new patents. The then newly granted patents brought the company’s total to 23 granted patents worldwide as of December 2021 (https://ibn.fm/xSXj1).

And in an announcement that fulfills part of the company’s expectations for 2022 as well as expands its impressive IP portfolio even further, Lexaria recently…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Imports First CBD Products from Colombia Operations to U.S., with National Distribution Boost from Recent JustCBD Acquisition

March 18, 2022 09:05:00
  • Flora Growth is a cannabis cultivator and distributor operating a 100-hectare (about 247-acre) harvesting site called Cosechemos in central Colombia’s favorable growing climate
  • Flora Growth has completed its first import of CBD-containing food and beverage products into the United States under its Mambe brand, thanks to Colombian regulatory changes in recent months allowing cannabis product exports
  • Flora has filed licenses for 23 cannabinoid-infused food and beverage products with Colombia’s INVIMA food and drug regulatory body
  • Imported Flora products will take advantage of the company’s U.S. distribution network customer database, which nearly doubled with last month’s acquisition of established CPG brand JustCBD
  • JustCBD has over 300 products, 300,000 customers, and a network of over 14,000 stores across the United States and Flora’s operations will increase its capacity for international growth

The recently announced successful import of Mambe CBD-containing food and beverage products into the United States from Colombia marks a huge step for cannabis cultivator Flora Growth (NASDAQ: FLGC) in the company’s plans for becoming a global market distributor. 

Flora Growth’s 100-hectare (about 247-acre) Cosechemos cannabis cultivation site in central Colombia is key to its strategy, drawing on ideal conditions for cannabis production that include over 12.5 hours of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX), a Global Innovator in Drug Delivery Platforms

March 10, 2022 11:05:00
  • Lexaria’s patented DehydraTECH technology proved effective for sildenafil delivery in animal study PDE5-A21-1
  • The company also made some notable strides with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD
  • By doing so, it hopes to capitalize on the growing cardiovascular drugs market, which is projected to be valued at $107.8 billion by 2025 (https://cnw.fm/8bk1Y)
  • With the success of its studies thus far, the company seeks to conduct even more trials over the 2022 calendar year

Lexaria Bioscience (NASDAQ: LEXX) has, since its inception, remained committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs. Through its patented DehydraTECH(TM) drug delivery technology that began development in 2014, the company is offering potential solutions for conditions including, but not limited to hypertension, smoking cessation, anti-viral treatments, and other drug classes.

In what has marked a landmark achievement for Lexaria, its DehydraTECH technology proved effective for sildenafil delivery in an animal study conducted on lab rats. In addition, the study demonstrated that this technology offered…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals Inc. (NASDAQ: INM) Updates Recent Product Diversification Efforts and Strategic Acquisitions Developments; Announces VP Of Sales & Marketing Appointment

March 9, 2022 09:35:00
  • In a recent update, InMed Pharmaceuticals president and CEO, Eric A. Adams, lauded the company’s progress and achievements so far, particularly with its product diversification and strategic acquisitions 
  • Adams noted the company’s commitment to launching more products and executing more programs to continue growing its product portfolio 
  • InMed also announced the appointment of Gerald (“Jerry”) P. Griffin III as Vice President of Sales and Marketing at BayMedica, its wholly-owned subsidiary

In a conference call and webcast on February 15, 2022, Eric A. Adams, President and Chief Executive Officer of InMed Pharmaceuticals (NASDAQ: INM), emphasized the company’s successful product diversification and strategic acquisition achievements. Most notably, he expressed his optimism regarding the company’s expansion into the health and wellness sector as an ingredient supplier, coupled with the integration of BayMedica’s operations and team into its ongoing activities (www.cnw.fm/x7dza).

While noting how recent product launches have allowed the company to top its revenue estimates, Mr. Adams was also keen to point out its ongoing commitment to launch…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Strengthens Foothold in U.S. Wellness Market with Acquisition of JustCBD, Appoints Jessie Casner as CMO

March 9, 2022 09:35:00
  • Flora Growth owns and operates a portfolio of brands offering wholesale products, consumer packaged goods, or pharmaceutical and medical products
  • The three-pronged operational approach has allowed the company to substantially expand and accelerate its revenue growth over the short term
  • Recently, Flora Growth added yet another brand, JustCBD, to its portfolio; JustCBD’s performance is expected to immediately contribute to FLGC’s 2022 revenues and earnings
  • Flora Growth also appointed Jessie Casner as the Chief Marketing Officer; Ms. Casner will lead communications, narrative building, and consumer marketing strategies, in addition to crafting brand awareness activities

Founded on the premise of becoming a global leader in the cannabis trade, Flora Growth (NASDAQ: FLGC) is progressively developing an ecosystem that will support market-leading innovation, all in a mission to build a design-led collective of plant-based wellness and lifestyle brands. The company has expanded rapidly through existing and new brands operating in the cannabis & hemp, food & beverage, skincare & cosmetics, lifestyle & apparel, ancillary & technology, and nutraceuticals & wellness segments.

In explaining the motivation behind building a large, ever-growing ecosystem of brands, CEO Luis Merchan recently stated that “as a cannabis company, we need to ensure that we have the ability to penetrate a market with certain…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC 

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Studies Advance Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology for Significantly Improving Pharmaceutical Drugs

March 4, 2022 09:20:00
  • Lexaria Bioscience is dedicated to applying its patented technology to pharmaceutical drug offerings to enhance their performance and speed their rate of effective use
  • The company’s flagship DehydraTECH(TM) technology has delivered numerous successes in studies of its potential for treating high blood pressure and heart disease, nicotine addiction, and virus infection
  • Most recently, the company reported successes in increasing the speed and effectiveness in a drug treating erectile dysfunction (“ED”) in laboratory animals
  • Lexaria is preparing an investigational new drug (“IND”) application for its hypertension line of study with the aim of achieving a new drug application (“NDA”) approval from the FDA

The recent announcement that drug bio-effectiveness innovator Lexaria Bioscience’s (NASDAQ: LEXX) patented DehydraTECH(TM) technology may be useful in erectile dysfunction therapy by enhancing the speed of effectiveness of medication sildenafil (common as Viagra) follows on a number of developmental successes reported by Lexaria. 

DehydraTECH is a proprietary technology that changes how the body detects and absorbs drugs by combining active pharmaceutical ingredients (“APIs”) with a fatty acid oil, applying it to a food or other type of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

As It Targets Multiple Large Market Opportunities, Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Leveraging Elaborate Studies to Progressively Remove Risks Associated with Commercialization, Regulation

February 28, 2022 09:20:00
  • Leveraging the versatility and benefits of its DehydraTECH(TM) technology, Lexaria is targeting multiple large market opportunities as it attempts to ensure it has multiple paths to success
  • The technology aims to help companies offering oral drugs, supplements, and nicotine formulations to improve the effectiveness of their existing or planned products
  • Lexaria has undertaken various studies whose findings show the benefits of DehydraTECH-processed products relative to controls
  • The company intends to use the positive results from its studies to incrementally remove risks associated with commercialization and regulation

Lexaria Bioscience (NASDAQ: LEXX), a global drug delivery technology company transforming existing consumer products and medication by increasing their bioavailability, speed of onset, and brain absorption, is currently targeting multiple large market opportunities, ranging from cardiovascular drugs, antivirals, human hormones, and phosphodiesterase inhibitor (“PDE5 inhibitor”) formulations to nicotine replacement, and cannabidiol (“CBD”).

“We are currently pursuing or investigating several large market opportunities, the smallest of which is currently generating over $10 billion in annual revenue. In many of these markets, growth is expected to be significant over the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About its Expanded DehydraTECH Investigations; Plans for More Studies in 2022

February 23, 2022 10:20:00
  • Lexaria just announced ground-breaking findings from its recently-concluded Sildenafil animal study
  • The success of this study sets the stage for various other studies on the use of the company’s patented DehydraTECH technology
  • The company is set to commence dosing its most extensive hypertension study in April 2022, with results expected in Q3 2022
  • Its successful completion could greatly enhance Lexaria’s leadership position in the global drug delivery market

Lexaria Bioscience (NASDAQ: LEXX) kicked off the 2022 calendar year by receiving independent review board approval for its upcoming DehydraTECH(TM)-CBD human hypertension study, HYPER-H21-4.  Additionally, in what marks another critical milestone, the company also reported ground-breaking findings from its sildenafil animal study.

Chris Bunka, the Lexaria’s Chief Executive Officer (“CEO”), at the beginning of the year, noted the company’s commitment to achieving even more milestones with its patented DehydraTECH technology for…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

Flora Growth Corp. (NASDAQ: FLGC) Focused On Opportunities in the CBD Industry to Scale Operations

February 18, 2022 09:35:00
  • Luis Merchan, Flora Growth’s President and CEO, appeared on a webinar on February 11, 2022, highlighting the opportunities and challenges affecting the CBD industry in key markets
  • He has reiterated the company’s commitment to leveraging the industry’s opportunities for the growth of its operations, expansion of its market reach, and value creation for its shareholders
  • The CBD industry is projected to be valued at $20 billion by 2025, and Flora Growth plans to capitalize on this growth

In 2020, CBD sales in the United States reached $4.6 billion. It is projected that by 2024, this industry will be valued at $15 billion and $20 billion by 2025. For a federally illegal product up until 2018, this industry has grown tremendously and shows even greater promise for growth in the coming years (https://cnw.fm/h15ED).

Flora Growth (NASDAQ: FLGC), an internationally-focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives, recognizes…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Summarizes 2021 Milestones, Outlines 2022 Plans and Expectations, in Annual Letter to Shareholders

February 8, 2022 13:56:10
  • In 2021, Lexaria conducted several main studies evaluating DehydraTECH-processed CBD and nicotine
  • The company has big plans for 2022, a year it expects to undertake three ground-breaking studies
  • Lexaria hopes these three major studies will generate sufficient data to support either regulated IND-type applications or to stimulate corporate partnerships
  • The company is eying larger national and international applications for DehydraTECH with the aim of generating revenue through licensing fees and royalties

For Lexaria Bioscience (NASDAQ: LEXX), a drug delivery company whose patented DehydraTECH(TM) technology has proven effective in improving bioavailability, speed of onset, and efficiency of orally-delivered fat-soluble active molecules and pharmaceuticals, 2021 was a year of myriad milestones. In an annual letter to shareholders, company CEO Chris Bunka underlined that January 2021 marked the birth of a modern version of the company (https://cnw.fm/Hli8Z).

“During 2021, we completed research & development (‘R&D’) and validating work equal to or greater than all the combined amount previously completed since…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals Inc. (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market Following New Product Launch, Key Acquisition

February 3, 2022 14:26:12
  • Cannabicitran is the first of four new rare cannabinoids InMed is planning to launch in the first half of the year to meet growing inbound demand
  • The launch demonstrates InMed’s ability to produce rare cannabinoids at scale, something only very few companies have achieved
  • BayMedica acquisition, other key achievements in 2021, are positioning the company as a leading supplier of rare cannabinoids in the health and wellness sector

A leader in the research, development, manufacturing and commercialization of rare cannabinoids, InMed Pharmaceuticals (NASDAQ: INM) has begun the new year from a more prominent position in the market, following key acquisitions and milestones attained in 2021 and the launch of a new product, cannabicitran (“CBT”). The company is uniquely positioned to leverage the worldwide growing awareness of the potential benefits of cannabinoids and a rising demand for rare cannabinoids in particular (https://cnw.fm/uQXcU). 

According to Grand View Research, the rare cannabinoid retail market is anticipated to reach $26 billion by 2028 (https://cnw.fm/CNIA7). Commercial scale access to rare cannabinoids will enable consumer brands and product manufacturers to deliver differentiated products as well as…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Blazing Trail in Defining Value of Rare Cannabinoids in Pharmaceutical Space

February 2, 2022 15:01:12

InMed Pharmaceuticals (NASDAQ: INM) is a trailblazer, a pioneer defining the value of rare cannabinoids in the pharmaceutical sector and just how integral they are in pushing the industry forward. The global cannabis market is experiencing tremendous growth, particularly considering there are over 100 known cannabinoids, including rare ones that are quickly taking over and will soon dominate the market. The potency of rare cannabinoids has given them powerful health benefits, hence their demand within the cosmetics, food and beverage, health and wellness, and pharmaceutical sectors. “InMed’s most advanced compound, INM-755, has already proven helpful in treating epidermolysis bullosa, a severe genetic disorder… InMed is also working on its INM-008 compound for the treatment of glaucoma and is currently evaluating different formulations to deliver ocular cannabinoids into the eye,” a recent article reads. “InMed is not just focusing on rare cannabinoid research but also investing time and resources into its manufacturing process. So far, this process allows for cannabinoid synthesis to create compounds in the laboratory that are bioidentical to those derived from the cannabis plant.”

To view the full article, visit https://cnw.fm/b53YV

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com and www.BayMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Sets to Benefit Amid a Rapidly Growing Market

February 2, 2022 14:45:37
  • BevCanna is company developing diversified portfolio of health and wellness products for both in-house brands and white-labeled clients
  • Company deploys a traditional retail and direct-to-consumer e-commerce model to offer products throughout North America
  • Company actively explores opportunities within infused beverages market as CBD-infused beverages gain popularity; global market expected to reach US$2 billion by 2026

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) is a Canada-based diversified health and wellness beverage and natural products company developing and manufacturing a diverse portfolio of alkaline, plant-based, and cannabinoid beverages and supplements for in-house brands and white-label clients alike. Founded in 2017, BevCanna was quick to leverage a unique value that its team of established beverage experts brings to the table – deep knowledge of consumer preferences and buying behavior that inspires the creation of products that appeal to consumers at a mass scale.

Committed to promoting wellbeing and quality of life through products it creates, the Company sees an opportunity in the infused beverages market as consumers seek new products that are aligned with a more health-conscious lifestyle. ReportLinker, an AI-driven market intelligence company, finds that the global cannabis beverages market is expected to reach…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://cnw.fm/BVNNF

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Recent Access of Manufacturing Technologies Now Give It the Potential to Synthetically Produce Rare Cannabinoids at Large Scale, a Unique and Coveted Position in the Rapidly Developing Rare Cannabinoid Space

February 1, 2022 15:13:14
  • Rare cannabinoids are cannabinoid compounds other than CBD and THC which are not yet produced in large scale but which have potentially greater benefits
  • InMed acquired BayMedica in October 2021, bringing on board unmatched expertise in large-scale bio-production technologies applicable to rare cannabinoids
  • As a result of this acquisition, InMed, already a leader in the production of rare cannabinoid CBC, is now in the unique and highly desired position to undertake large-scale production of other rare cannabinoids, with applications as wide as the current CBD market
  • The company plans to launch new rare cannabinoid products in the first half of 2022

The human body naturally produces cannabinoids – endocannabinoids such as anandamide (“ANA”) – as part of a physiologic system that maintains human health by reducing inflammation and promoting homeostasis (https://cnw.fm/TPyZy). So named after the plant that led to its discovery, the endocannabinoid system (“ECS”) however only produces two known cannabinoid compounds, while over 140 variants can be found in the cannabis plant, most in trace amounts. 

Of the latter group of cannabinoids, cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) are the most common. Researchers have in fact studied both…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Offers a Glimpse into Company’s Unique Technology and Operations on EDGE Podcast

January 31, 2022 14:19:49
  • Chris Bunka, the Chairman and CEO of Lexaria, featured on the EDGE podcast hosted by Brandon C. White
  • He provided insight into his background, professional philosophies, and Lexaria’s operations, with a focus on the company’s patented DehydraTECH(TM) technology
  • Mr. Bunka also advised small companies and entrepreneurs, citing the importance of understanding the competitive environment

Chris Bunka, the Chairman and Chief Executive Officer (“CEO”) of Lexaria Bioscience (NASDAQ: LEXX), was recently featured on episode 234 of the EDGE Podcast. Hosted by Brandon C. White, an Angel Investor and Entrepreneur, Mr. Bunka shared insights into his professional journey while also sharing what the company is committed to achieving going forward. 

Mr. Bunka lauded the company’s patented DehydraTECH(TM) technology, citing how integral it is to improve the delivery of active pharmaceutical ingredients and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs Following Independent Review Board Approval

January 20, 2022 14:20:42
  • Lexaria received independent review board approval for its HYPER-H21-4 human clinical study for hypertension treatment
  • The stage is also set for other R&D programs for the 2022 calendar year, including HOR-A22-1, DEM-A22-1, RHEUM-A22-1 and DIAB-A22-1
  • All of these 2022 R&D programs are fully funded, with Lexaria having raised approximately $15 million over the 2021 calendar year
  • Lexaria believes that these programs will build significant value for its stakeholders and pursue policies for substantial improvements to human health

In late 2021, Lexaria Bioscience (NASDAQ: LEXX) announced several new and ongoing R&D programs for its patented DehydraTECH(TM) technology. While making the announcement, Chris Bunka, the Chief Executive Officer (“CEO”), noted that Lexaria would continue to see significant milestones in utilizing DehydraTECH-CBD, focusing on heart disease and hypertension.

“Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About HempWire

HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.HempWire.com/Disclaimer

Do you have a questions or are you interested in working with HW? Ask our Editor

HempWire (HW)
Denver, Colorado
www.HempWire.com
303.498.7722 Office
Editor@HempWire.net

HempWire is part of the InvestorBrandNetwork.

After a Successful 2021, Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off 2022 With New Media Strategy, Plans for Clinical Study Advancements

January 14, 2022 09:15:00
  • Lexaria has multiple studies planned that will commence early in 2022
  • DehydraTECH increases Lexaria’s ability to leverage multiple markets, including the growing CBD sector, which is expected to meet and exceed $108 billion in revenue by 2027
  • DehydraTECH can increase the efficacy of the drugs being administered, offering faster absorption and lowering the delivery time

In a strategic move to start off 2022, Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, has announced that it has signed an advertising and media contract with financial technology company SRAX (NASDAQ: SRAX). The contract will facilitate media buys and digital marketing by SRAX on behalf of Lexaria. This announcement is only the beginning of what the company anticipates to be the busiest year yet.

Chris Bunka, CEO of Lexaria, was more than pleased with the contract signed and with SRAX, and he voiced optimism about the year-long campaign that has commenced and its outcomes. “Lexaria has made tremendous progress during…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWire: Text “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Distribution Deal Increases CBD Product Reach to Mexico, Latin America

January 12, 2022 09:45:00
  • Plant-based wellness and lifestyle brand cultivator Flora Growth Corp. is building on its initial revenues from 2021 with distribution expansion into Mexico
  • The company will initially distribute a portfolio of 12 Mind Naturals skincare products through e-commerce but intends to eventually locate its products in brick-and-mortar stores
  • The company’s deal with Mexican department store Coppel gives it a reach nationwide through its online marketplace and, perhaps eventually, Coppel’s 1,253 stores
  • Flora Growth’s products will also be distributed through global retail giant Walmart’s e-commerce platform — one of the leading retail chains in Central America
  • The company also has an outdoor cultivation segment with operations based in central Colombia, where cannabis can be grown at a fraction of the cost of cultivation in the United States, helping Flora Growth to boost its potential profitability and competitiveness
Flora Growth (NASDAQ: FLGC) is expanding its cannabis-derivative brand presence in Latin American countries through cannabidiol (“CBD”) product distribution deals with global retailer Walmart’s online marketplace and Mexican department store chain Coppel’s e-commerce outlet. Flora Growth’s Mind Naturals skincare brand, built with premium CBD and other high-quality ingredients, as well as the company’s Awe CBD skincare brand, began rolling out in… Read More>> NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates Productive Year for Blood Pressure Drug Solution with Eye on Advancing Clinical Studies in 2022

January 12, 2022 09:15:00
  • Lexaria Bioscience’s ongoing human clinical studies for its patented and trademarked DehydraTECH technology have yielded progressively optimistic results in 2021 regarding DehydraTECH’s ability to provide effective solutions for the cardiovascular industry
  • DehydraTECH is being studied for its capacity to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability of a generic CBD formulation
  • DehydraTECH-CBD underwent three human clinical studies in 2021 that examined its ability to reduce arterial stiffness and blood pressure without creating unintended negative consequences
  • A fourth, more comprehensive study was approved at year’s end, as the next step in the strategy, and dosing is tentatively expected to begin by April

Health and wellness drug bio-effectiveness innovator Lexaria Bioscience (NASDAQ: LEXX) is celebrating its multiple successes during 2021 after capping the year with regulatory approval for the most comprehensive study to date of its patented and trademarked technology as a potential treatment for hypertension. 

Study protocols for HYPER-H21-4 were prepared as a continuation of 2021’s HYPER-H21-1 through HYPER-H21-3 studies that examined the capability of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWire: Text “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Independent Review Board Approval for Its Most Ambitious, Comprehensive Human Study Yet

January 10, 2022 13:37:02
  • Lexaria has received approval from the Independent Review Board for its DehydraTECH-CBD Human Clinical HYPER-H21-4 study
  • The approval signals the company has taken the appropriate steps to protect the rights and welfare of human subjects participating in its fourth human study
  • HYPER-H21-4 should “de-risk” outcomes prior to Lexaria’s planned entry into regulatory pathways for the use of DehydraTECH-CBD to treat hypertension and perhaps other forms of cardiovascular disease
  • Previous studies – HYPER-H21-1 and HYPER-H21-2 – have evidenced a remarkable, rapid, and safe drop in blood pressure with DehydraTECH-CBD

A little less than two months after Lexaria Bioscience (NASDAQ: LEXX) announced it was readying the study protocols for HYPER-H21-4, its most ambitious and comprehensive study yet, for submission to the Independent Review Board (“IRB”) with approval anticipated by January 2022 (https://cnw.fm/xCGhl), the company is celebrating the receipt of the approval ahead of schedule. 

An administrative body created to safeguard the rights and welfare of human subjects recruited to participate in research activities, the IRB is tasked with…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX 

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWire: Text “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

Lexaria Bioscience Corp. (NASDAQ: LEXX) Increases Investor Visibility with SRAX Inc. (NASDAQ: SRAX)

January 6, 2022 14:07:28
  • The strategic move to incorporate SRAX is designed to bring investor visibility for all of the upcoming events that Lexaria has planned for 2022
  • Lexaria’s patented DehydraTECH(TM) technology is poised to leverage multiple industries – notably the CBD industry, with a projected value of $108.8 billion by 2027
  • The advertising and media contract will allow SRAX to engage and manage social media companies for the creation and distribution of advertising materials promoting Lexaria Bioscience

Lexaria Bioscience (NASDAQ: LEXX), an innovator of drug delivery platforms, announced that it will kick off 2022 with an advertising and media agreement with SRAX (NASDAQ: SRAX) for media buys and digital marketing. The announcement is the first in a long line of plans that the company has made for the new year, a year anticipated to be the busiest yet for the company. The strategic move to bring on SRAX will help Lexaria increase its visibility to the investor community, enhancing the company’s exposure across all networks (https://cnw.fm/I9J5a).

Lexaria’s advertising and media contract with SRAX allows the latter to engage and manage media companies to create and distribute advertising materials made available online. SRAX will control when these communications are…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX 

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWire: Text “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Entering 2022 with Momentum from Sustainability Efforts and the Building of Global Distribution Channels

January 3, 2022 14:41:47
  • Flora Growth Corp. is a Canadian cannabis and wellness brand distributor operating from a cultivation base in central Colombia
  • The company’s focus on sustainability guides its efforts to market products that are beneficial to their local communities as well as the world at large
  • Market analysts predict 2022 will see the global CBD skin care market segment alone grow with a CAGR of 24.8 percent
  • The COVID-19 pandemic is continuing to drive expansion of online retail that affects the cosmetics sector as well as clothing, groceries and other avenues that may include the more-than-190 cannabis-derivative products produced by Flora Growth 

Plant-based wellness and lifestyle collective Flora Growth (NASDAQ: FLGC) is entering 2022 with momentum from the past year’s aggressive growth campaign for its global cannabis-derivative brand distribution of pharmaceuticals, cosmetics and nutraceuticals. .

While industry news has largely focused on M&A activity and questions about when the United States may grant federal legalization of cannabidiol (“CBD”) following the advance and then defeat of supportive banking measures in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Marks 2021 Close with Product Diversification and Market Expansion

December 27, 2021 14:27:24
  • Flora Growth recently expanded into Mexico and Spain with its Mind Naturals and Awe CBD skincare brands
  • Additionally, the company ventured into the dry herb market through Vessel brand, its wholly owned subsidiary
  • The recent licensing agreement with Tonino Lamborghini marks Flora Growth’s aggressive product diversification plan that has defined its 2021 calendar year
  • All the decisions and moves made by the company so far have been geared toward growing the company’s market share, expanding its market reach, and increasing value for its shareholders
Flora Growth (NASDAQ: FLGC) completed its first traditional cannabis Initial Public Offering (“IPO”) in May 2021. Within seven months, the company has embarked on an aggressive market expansion and product diversification plan geared toward stamping its position within the cannabis brand space and creating value for its shareholders. Its latest move was expanding into Mexico and Spain with its Mind Naturals and Awe CBD skincare brands (https://cnw.fm/GZRvY). These products, targeted toward younger consumers and the prestige market respectively, incorporate present-day consumers’ expectations by… Read More>> NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

Marijuana Company of America Inc. (MCOA) Completes VBF Brands Acquisition, Highlighting Growth Strategy

December 27, 2021 14:24:25
  • Marijuana Company of America, Inc. has been expanding its portfolio in recent months through acquisitions and partnerships designed to enhance the company’s revenue stream
  • MCOA’s trademarked hempsmart brand of CBD products has been joined by verticals including marijuana cultivator and distributor VBF Brands, CBD brands distributor cDistro, in-store advertiser VapeTV US, and other industry solutions
  • The recent completion of VBF Brands’ acquisition grants MCOA efficiency and sustainable cultivation techniques in its product development
  • Efforts to expand the legalization of recreational and medicinal marijuana at the federal level have been gaining steam again, portending significant opportunities for growth in 2022
As the COVID pandemic nears the beginning of its third year as a global health and economic crisis, the persistence of the underlying virus’ ability to make news with its alterations of everyday life activities continues to sew a measure of insecurity into the fabric of society (https://cnw.fm/KKRus). Amid the concerns generated by the virus’ continued infectiousness, the momentum to establish free access to cannabis’ wellness and recreational properties has gained renewed vigor, heralding the potential for… Read More>> NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://cnw.fm/MCOA About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office Editor@CBDWire.com

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expects Study Results to Show its Patented Tech’s Value in Treating Hypertension Patients

December 27, 2021 14:23:38
  • Lexaria Bioscience is preparing to file an Investigational New Drug application with the U.S. Food and Drug Administration for its patented technology’s use in treating hypertension (high blood pressure)
  • The company has completed multiple studies of the benefits of DehydraTECH(TM), in combination with cannabidiol to combat hypertension conditions and consequentially benefit cardiovascular patients
  • Lexaria recently announced that it is nearing completion of a third human study in which the company expects to further explore whether DehydraTECH-CBD successfully treats high pulmonary blood pressure
  • A comprehensive six-week human clinical study is expected to begin soon
Lexaria Bioscience (NASDAQ: LEXX) is nearing completion of a human clinical study it believes will further its claims that its patented DehydraTECH(TM) technology works effectively with cannabidiol (“CBD”) as a potential treatment for hypertension, which has further potential implications for cardiovascular disease patients. Lexaria’s DehydraTECH technology works with drug substances which are orally ingested and enhances how they are processed into the blood stream without adverse consequences from the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office Editor@CBDWire.com

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Major Discovery; Increasing the Effectiveness of Orally Administered CBD

December 22, 2021 13:32:19
  • In a recent human clinical trial, HYPER-H21-2, DehydraTECH™-CBD reduced arterial stiffness, potentially broadening Lexaria’s application’s ability to treat cardiovascular and other diseases beyond hypertension
  • Lexaria’s patented technology DehydraTECH improves how APIs enter the bloodstream –making multiple benefits possible such as increased delivery speed, increase in brain absorbency, higher bioavailability, and lower costs
  • The company has patent protection received for delivery of nicotine, vitamins, NSAIDs, terpenes and cannabinoids; and patents pending for delivery of estrogen, testosterone, PDE5 inhibitors, antiviral drugs and more
Oral absorption is the most convenient and widely used administration route for taking medications. Decades of research have advanced the understanding of critical factors – anatomical, physiological, and drug information – which control oral bioavailability. Scientists are now better understanding the physiological function and formulation functionality that has been used in designing better and more desirable oral medicine delivery through extensive research. Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, is accomplishing this through its patented DehydraTECH(TM) technology. DehydraTECH(TM) improves the way that active pharmaceutical ingredients (“APIs”) make their way into the bloodstream. This is achieved by promoting healthier ingestion methods and an increase in the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office Editor@CBDWire.com

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Reduces Arterial Stiffness in Study HYPER-H21-2 Broadening Applications Beyond Hypertension

December 17, 2021 09:15:00
  • Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood pressure)
  • The company’s studies earlier this year indicated the potential of DehydraTECH to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability of a generic CBD formulation
  • Arterial stiffness is a noted indicator of diseases such as heart, kidney and pancreas organ ailments that increase mortality with age, therefore the ability to reduce arterial stiffness may have implications for improving human wellness and longevity
  • HYPER-H21-2 results evidence DehydraTECH-CBD reduces arterial stiffness
Lexaria Bioscience (NASDAQ: LEXX), an innovator in how drugs are utilized by the human body, is reporting newly found benefits from cannabidiol (“CBD”) enhanced by Lexaria’s patented DehydraTECH(TM) technology. The company’s Dec. 8 news release notes that DehydraTECH-formulated CBD was found to reduce arterial stiffness in mild-to-moderate hypertension (high blood pressure) patients volunteering in Lexaria’s HYPER-H21-2 human clinical study (https://cnw.fm/zIrF2). The company believes… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office Editor@CBDWire.com

Lexaria Bioscience Corp. (NASDAQ: LEXX) Participates in the Benzinga Global Small Cap Conference; Committed to Innovation and Improving Quality of Life

December 14, 2021 14:42:03
  • Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021
  • The event came right after the company announced human clinical hypertension study HYPER-H21-4, its most ambitious one yet
  • Lexaria plans to sublicense its patented DehydraTECH(TM) technology worldwide, allowing for more people to benefit from it
  • Going into 2022, the company looks forward to reporting on results from its HYPER-H21-3 clinical study and receiving Independent Review Board (“IRB”) approval for its HYPER-H21-4 study
Lexaria Bioscience (NASDAQ: LEXX) just participated in this year’s Benzinga Global Small Cap Conference. The two-day event was a showcase for small cap investing, bringing together shareholders, entrepreneurs, and investors. George Jurcic, the head of Investor Relations (“IR”) at Lexaria, represented the company. He was among 50 other speakers who took the stage in this event that featured 15-minute company presentations… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office Editor@CBDWire.com

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Totaling Over $160 Billion

December 10, 2021 13:39:55
  • Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022
  • The programs are designed to explore the ability of the company’s patented DehydraTECH(TM) to improve drug delivery processes for multiple indications
  • Research will continue into the use of DehydraTECH-CBD for high blood pressure, as well as the technology’s potential for oral nicotine delivery
Diabetes, rheumatoid disease, Alzheimer’s Disease, and estrogen delivery, are some of the multiple indications that drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX) is planning to target with its research and development programs next year. The markets targeted provide multiple opportunities for success and are now expected to reach an overall estimated value of more than $160 billion annually, worldwide over the next few years. The company will conduct pharmacokinetic and efficacy modelling studies to determine if its patented DehydraTECH(TM) technology can be used successfully to improve delivery of drugs or active pharmaceutical… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office Editor@CBDWire.com

Flora Growth Corp. (NASDAQ: FLGC) Launches European and Mexican Exports of CBD Skincare Brands

December 9, 2021 14:48:14
  • Colombian cannabis cultivator and international wellness product builder Flora Growth Corp. is building a global pipeline for its wide array of branded CBD and medicinal cannabis products
  • The company recently announced that it has begun fulfilling the first orders for its Mind Naturals and Awe CBD skincare brands with exports to Spain and Mexico outlets this month
  • Flora Growth cultivates cannabis at its 100-hectare (247-acre) property in central Colombia
  • Flora also has a GMP certified 16,000-square-foot manufacturing facility in Bogota that produces nearly 200 products for the CBD derivatives and medical cannabis markets
Cannabis cultivator and worldwide cannabidiol (“CBD”) brand builder Flora Growth (NASDAQ: FLGC) continues to expand its consumer product goods and wellness lifestyle technology internationally, recently receiving its first orders for its Mind Naturals and Awe CBD skincare brands from outlets in Spain and Mexico. The company’s e-commerce agreements with SHOWFIELDS and GlossWire’s digital beauty marketplace in October paved the way for the two skincare brands to roll out in international markets. Fulfillment of these initial purchase orders from Amma Spain and Mexico’s… Read More>> NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – Grapefruit USA Inc. (GPFT) Launches World’s Most Effectively Bioavailable CBD Delivery Cream

December 6, 2021 13:22:29

Grapefruit USA (OTCQB: GPFT), a premiere California-based cannabis and hemp company, today announced the official launch of the world’s first patented time-release, hemp-based CBD topical cream with boosted bioavailability, made possible by its proprietary Hourglass(TM) technology. Hourglass, a unique method for topical delivery of CBD, leverages a proprietary process that involves the grinding of CBD into nano-sized particles, substantially smaller than the width of a human hair, which allows for significantly higher bioavailability and absorption. “Over the last several months, our Hourglass product team has received extremely positive product feedback and internal reviews from our product testers and retail customers after their regular use of our hemp-based CBD Hourglass topicals, which is extremely gratifying for the company and at base shows that the technology works,” said Bradley Yourist, CEO at Grapefruit USA. “Grapefruit’s Hourglass Topical Delivery Cream will fundamentally change the way individuals use CBD and other cannabinoids to obtain their holistic benefits.”

To view the full press release, visit https://cnw.fm/XG8oJ

About Grapefruit USA Inc.

Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. Grapefruit’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Road, approximately 14 miles north of downtown Palm Springs. For more information about the company, visit www.GrapefruitBlvd.com.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Enters Cannabis Beverages Market, Extends Portfolio of Luxury Products with Tonino Lamborghini Licensing Agreement

December 3, 2021 09:15:31
  • Flora Growth recently entered into a licensing agreement to produce and distribute Tonino Lamborghini-branded cannabis beverages across North America and Colombia, with an initial focus on the U.S. market
  • The company will produce the product line using molecular tagging and authentication technology that will guarantee product verification and allay concerns of counterfeit products
  • Through the licensing agreement, Flora has entered into the cannabis beverages market amid increasing demand for CBD-based products
  • The recent agreement follows a November 15 announcement that FLGC had completed the acquisition of Vessel Brand Inc., an industry leader in luxury cannabis consumer technology
Internationally focused cannabis brand builder Flora Growth (NASDAQ: FLGC) recently signed a licensing agreement with Tonino Lamborghini, a luxury brand operating in the high-end designer products, hotel, beverage, and real estate segments. Under the terms of the partnership announced November 29, Flora Growth will produce and distribute Tonino Lamborghini-branded cannabis beverages across North America and Colombia (https://cnw.fm/TEm9L). The Tonino Lamborghini product line, which will be produced in Florida for initial sale in US states where cannabidiol (“CBD”) ingestible are legal, will contain CBD and other premium cannabinoids, including cannabigerol (“CBG”). In addition, Flora will produce the product line using… Read More>> NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Inks Agreements with Leading Health and Beauty Company, CBD Beverage Company

November 29, 2021 12:35:56

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has signed a definitive agreement with Avaria Health & Beauty Corp. Based on the agreement, the two companies will form a joint venture (“JV”), named FloVaria Corp., aimed to facilitate the sale of its award-winning KaLaya brand; sales efforts will be directed in Latin America (“LATAM”). KaLaya has currently sold more than a million units throughout Canada and is carried in major retail locations including Walmart and Loblaws, where the brand has earned the number-two customer loyalty rating in the natural-value, skin-care category. The agreement increases the value of FLGC’s Colombian distribution channels, which currently numbers more than 2,500. The agreement calls for Flora Growth’s wholly owned, GMP-certified manufacturing facility to produce the cannabinoid-infused products that will be sold through the JV. In addition, Flora will be responsible for distribution, supply chain, and marketing support of KaLaya’s pain-management products in Colombia, Mexico and other LATAM countries, while Avaria will initially provide the finished product to the JV company. In addition, the company also announced that it is entering the cannabis beverage market. The company has entered a licensing agreement with Tonino Lamborghini to produce and distribute CBD beverages. The Tonino Lamborghini product line will launch early next year. Under the agreement, Flora Growth will retain the right of first refusal to distribute any cannabis products globally under the Tonino Lamborghini brand. “We are excited to partner with such a well-known luxury brand as Tonino Lamborghini, which already boasts a very successful line of beverages and aligns with Flora’s brand portfolio of high-end products,” said Flora Growth president and CEO Luis Merchan in the press release. “This partnership is yet another step in the execution of Flora’s strategic plan to build a world-class house of brands and is also a major component of our sales and distribution strategy in the lucrative U.S. market.”

To view the full press releases, visit https://cnw.fm/5mFg2  and https://cnw.fm/Zxj8Y

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that delivers the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. For more information about the company, please visit www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications

November 24, 2021 08:15:38
  • Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for DehydraTECH-CBD for potential use as a treatment for hypertension
  • HYPER-H21-4 will build on successes witnessed in initial human hypertension studies
  • The company, which has a fully funded R&D budget, recently announced new R&D programs covering multiple conditions, including dementia, diabetes, and rheumatoid disease
  • Lexaria is committed to improving lives and lessening deaths through its patented DehydraTECH(TM) technology
With a fully-funded research and development (“R&D”) budget, Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed, efficacy, bioavailability, and brain absorption of orally-delivered fat-soluble active pharmaceutical ingredients (“APIs”) through its patented DehydraTECH(TM) drug delivery technology  is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. In January 2022, Lexaria expects to report blood pressure findings from its third human hypertension study, HYPER-H21-3, building on the successes of the first two human studies, HYPER-H21-1 and… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About HempWire HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge. To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.HempWire.com Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.HempWire.com/Disclaimer Do you have a questions or are you interested in working with HW? Ask our Editor HempWire (HW) Denver, Colorado www.HempWire.com 303.498.7722 Office Editor@HempWire.net HempWire is part of the InvestorBrandNetwork.

Marijuana Company of America Inc. (MCOA) Set to Launch VapeTV U.S. in a Three-Way Partnership

November 24, 2021 08:15:00
  • MCOA just signed an LOI with VapeTV UK and Jasleen Enterprises for the launch of VapeTV U.S.
  • This new company is set to offer in-store advertising within retail vape stores
  • It will capitalize on the growing CBD industry and the ever-increasing demand for in-store media advertising in the United States
Marijuana Company of America (OTC: MCOA) has announced the signing of a non-binding letter of intent (“LOI”) that marks the beginning of the process to form a new in-store advertising brand named VapeTV US, Inc. (https://cnw.fm/jfcGM). VapeTV US will be the product of a three-way partnership among cDistro, Inc, a wholly-owned MCOA distribution company, VapeTV Ltd., a United Kingdom (“UK”)-based advertising company, as well as… Read More>> NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://cnw.fm/MCOA About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office Editor@CBDWire.com

CannabisNewsWire Recaps Success of ‘USA CBD Expo’ as Team Rebrands Event Series to ‘Alternative Products Expo’

November 16, 2021 08:45:03
Date: OCTOBER 28-30, 2022 Venue: Chicago With the recent completion of their jumbo event in Chicago, the USA CBD Expo team has rebranded their event series as ‘Alternative Products Expo’. Chicago’s USA CBD Expo, the country’s biggest CBD event and covering the largest assortment of hemp and CBD goods, imparted critical knowledge to niche company owners on how to reach new consumers and… Read More>> For more information regarding the USA CBD EXPO Chicago Event, kindly visit https://altproexpo.com/ About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarks on its Most Ambitious Hypertension Clinical Study Yet: HYPER-H21-4

November 12, 2021 13:30:36
  • Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and it’s most ambitious yet
  • This study builds on the HYPER-H21-1 and HYPER-H21-2 findings, as well as the HYPER-H21-3 study that is set to begin dosing in mid-November 2021
  • Lexaria’s goal is to pursue regulatory approval for its proprietary DehydraTECH-CBD for potential use as a treatment for high blood pressure
  • Study protocols are being readied for submission to the IRB, and approval is expected by January 2022
Lexaria Bioscience (NASDAQ: LEXX) has, so far in 2021, embarked on several studies geared towards evaluating its proprietary DehydraTECH(TM) CBD for the potential treatment of hypertension and heart disease. Results from the first hypertension study, HYPER-H21-1, were released on July 29, 2021, showing that the administration of a single dose of 300 mg of DehydraTECH-CBD resulted in a significant reduction in blood pressure from baseline. Of the 24 adult volunteers in… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX About CanadianCannabisWire CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CanadianCannabisWire.com Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CanadianCannabisWire (CNW) Toronto, Ontario www.CanadianCannabisWire.com 905.674.5977 Office Editor@CanadianCannabisWire.com CanadianCannabisWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – Endexx Corporation’s (EDXC) Popular Blesswell(TM) to Hit Shelves of Major Retail Chain

November 4, 2021 14:39:48

Endexx (OTC: EDXC), a provider of innovative hemp-derived cannabidiol (“CBD”) wellness and health products, today announced its receipt of a vendor number and cleared compliance with a major well-known drug chain for the placement of its BlessWell(TM) product line. Endexx has already begun the process of preparing products for shipment and placement by year-end into the national chain, and the initial arrangement will target approximately 1,000 stores in North America. The men’s skin care line, Blesswell, launched in May 2021 with famed record producer and music mogul, DJ Khaled. Blesswell has received high praise and mass exposure recently as many celebrity influencers have mentioned the product on social media. In addition, Chicago saw the successful launch of a large-scale, Blesswell pop-up store. Endexx’s goal for Blesswell is continued nationwide expansion, both in retail as well as barbershops.

To view the full press release, visit https://cnw.fm/bKy0A

About Endexx Corporation

Endexx, through its operating division CBD Unlimited Inc., develops and distributes all-natural CBD products derived from the cannabis sativa plant (hemp), containing less than 0.01% THC. Under its four major brands: CBD Unlimited, Phytobites, Maggie’s, and BlessWell, its products range from oils, capsules, topicals and pet products, all with the shared purpose of therapeutic and pain relief for humans and pets. PhytoBites are CBD soft chews for animal use that are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. The science behind these products involves over half a decade of clinical research in the field and lab work to provide accuracy in dosage and delivery of optimal absorption per serving. For more information about the company, visit www.Endexx.com.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio

November 3, 2021 12:51:39
  • Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD has similar or superior efficacy in reducing or inhibiting seizure activity compared to FDA-approved seizure drug, Epidiolex
  • The study will also compare DehydraTECH-CBD to generic CBD
  • EPIL-A21-1 has entered early-stage preparatory work, with results expected in Q3 2022
  • Lexaria received new patent awards in Mexico and Japan, strengthening its IP portfolio to 23 granted patents
Lexaria Bioscience (NASDAQ: LEXX), the drug delivery platform innovator behind the disruptive, patented DehydraTECH(TM) technology, recently announced it had commenced an important new animal study, EPIL-A21-1 (https://cnw.fm/iMVe3). EPIL-A21-1, which will be conducted by a talented team that includes respirology and neurology experts, will explore whether DehydraTECH-processed cannabidiol (“CBD”) evidences similar or superior efficacy in reducing or inhibiting seizure activity compared to Epidiolex, which is now sold by… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CanadianCannabisWire CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CanadianCannabisWire.com Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CanadianCannabisWire (CNW) Toronto, Ontario www.CanadianCannabisWire.com 905.674.5977 Office Editor@CanadianCannabisWire.com CanadianCannabisWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex

November 1, 2021 12:37:51

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1,designed to evaluate whether its DehydraTECH(TM)-CBD (“CBD”) indicates superior ability to reduce seizure activity compared to both generic cannabidiol and Epidiolex. Epidiolex is the only CBD medication approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of pediatric epilepsy. Among those involved in the study are respirology and neurobiology experts. According to the announcement, the team of investigators will carefully analyze how DehydraTECH-CBD compares with Epidiolex in treating seizures. LEXX noted that the company developed its seizure program because of the significant gains in systemic delivery and brain uptake that had been seen repeatedly in its own studies as well as other studies comparing DehydraTECH-CBD with concentration-matched controls. Lexaria also announced that it has received its first patent award for DehydraTECH in Mexico as well as another patent in Japan; the Mexico award protects the proprietary drug-delivery system for use with cannabinoids and nicotine while the Japan patent covers the use of DehydraTECH utilizing nonpsychoactive cannabinoids, nicotine, vitamins or nonsteroidal anti-inflammatory (“NSAID”) substances. The Japan award is the fifth patent the company has been awarded in 2021. The company currently has 23 granted patents from the United States, Australia, the European Union, India, Japan and Mexico that protect DehydraTECH.

To view the full press release, visit https://cnw.fm/0OoFx

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption of cannabinoids and nicotine by 5 to 10 times as well as reduce time of onset from one to two hours to minutes and mask unwanted tastes. The delivery systems are also being evaluated for orally administered, anti-viral drugs and nonsteroidal, anti-inflammatory drugs (NSAIDs) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth (FLGC) Receives Global Medical Cannabis Certification, Launches New CBD Brand

October 29, 2021 13:28:52
  • Flora Growth Corp. is an international cannabis consumer packaged goods distributor and cultivator based in Colombia that has built an ecosystem that will support market-leading innovation within categories that matter most to consumers exploring plant-based consumer goods.
  • The company recently obtained the Good Agricultural and Collection Practices (“GACP”) certification from international certification agency and global leader in medical cannabis certification Control Union Medical Cannabis Standard (“CUMCS”)
  • Flora Growth also just announced the launch of a new brand named Munzhi that will initially provide 12 CBD products for wellness, hair, body, and face benefits
  • Flora Growth’s Colombian operations are already producing more than 190 products, 63 of which are INVIMA-registered over-the-counter (“OTC”) products and have received three GMP certifications from the agency regulating Colombia’s food and drug trade
International cannabis brand builder and cultivator Flora Growth Corp. (NASDAQ: FLGC) is preparing to expand its global footprint with the development of a new collection of cannabidiol (CBD) wellness lifestyle products. Flora Growth’s Flora Lab division is launching the new Munzhi brand with 12 products across four categories: Wellness, Hair, Body, and Face. Launch efforts have been initially focused on the Colombian market, though the company will also be selling through an online shop and shipping around the world. Colombian President Ivan Duque loosened the country’s limits on cannabis trade in July, permitting the export of dry cannabis flowers used in food, beverage, cosmetics and textiles markets, and… Read More>> NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC), GlossWire Partner to Launch MIND Naturals and Awe (Ô) CBD Skincare Brands

October 28, 2021 11:02:36

Flora Growth Corp. (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, today announced that its Flora Beauty division has signed an agreement with GlossWire to feature its two skincare brands, MIND Naturals and Awe (Ô), on GlossWire’s digital beauty marketplace. The campaign launch with GlossWire, an innovative global marketplace featuring a highly curated mix of emerging and established brands, is expected to begin Nov. 10, 2021. “We are very excited to see an innovative technology platform like GlossWire seek our brands for their marketplace. This unique intersection of tech and beauty allows for discovery, storytelling and a deeper understanding of the customer,” said Luis Merchan, president and CEO of Flora Growth. “Partnering with a platform like GlossWire not only increases market awareness for MIND Naturals and Awe (Ô), but also allows us to further differentiate our brands by tailoring future products and offerings to our customers’ needs.”

To view the full press release, visit https://cnw.fm/J4TAQ

About Flora Growth Corp.

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Subsidiary Completes Development of Licensed Apopka Facility, Commences Cultivation Targeting Q4 Harvest

October 25, 2021 11:27:01
  • Red White & Bloom completed the build-out of its Apopka facility – phase one of a development strategy – and immediately commenced cultivation following the receipt of a cultivation license
  • The initial licensed area is projected to generate annual revenue in excess of $10 million
  • The Apopka facility will support phase two of the strategy, which entails the activation of thirty customized, self-contained growing pods
  • Phase three will involve the activation of a 113,000 SF facility for cultivation located in Sanderson
Upon closing the acquisition of an operational 45,000 square-foot greenhouse situated on 4.7 acres of land in Apopka, Florida in early August (https://cnw.fm/I3atY), the team at Red White & Bloom Florida LLC, a Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) subsidiary, embarked on the rapid development of the facility to ensure all compliance standards are achieved. The rapid development – build-out of Apopka – would constitute phase one of an aggressive three-phase development strategy for its Apopka and Sanderson facilities. In an October 12 press release, RWB announced that it had completed phase one of the strategy. In addition, having received regulatory approval to begin cultivation toward the end of… Read More>> NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://cnw.fm/RWBYF About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

New Study Underscores Rapidity of Oral Drug Bio-delivery Using Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology as an Alternative to Smoking and Vaping

October 22, 2021 12:04:49
  • Oral drug delivery innovator Lexaria Bioscience is focused on providing alternatives to smoked or inhaled tobacco and cannabis products to help consumers reduce the threat to their lungs
  • Lexaria’s patented technology — DehydraTECH(TM) — is a solution that processes active pharmaceutical ingredients into a powder or liquid form that can then be ingested with less harm than inhalation, while providing rapidity similar to inhalation substances
  • DehydraTECH has previously shown the ability to move CBD into test subjects’ bloodstreams up to 20-fold higher than standard generic formulations
  • New testing shows that DehydraTECH can similarly deliver THC to test subjects’ bloodstreams at rates faster and well above those of standard formulations for oral THC use
A leader in innovative drug delivery platforms, Lexaria Bioscience (NASDAQ: LEXX) aims to reduce or eliminate the use of inhaled and addictive products by focusing on ways to deliver nicotine into smokers’ bloodstreams at levels comparable to the nerve-settling relief they get from cigarettes and other tobacco products, providing them an alternative to purchasing store brands likely to harm their lungs. The company has enhanced its pursuit by testing its solution — its patented DehydraTECH technology — as an alternative to smoked or vaped cannabis products as well, and is reporting continued breakthroughs in… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CanadianCannabisWire CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CanadianCannabisWire.com Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CanadianCannabisWire (CNW) Toronto, Ontario www.CanadianCannabisWire.com 905.674.5977 Office Editor@CanadianCannabisWire.com CanadianCannabisWire is part of the InvestorBrandNetwork.

The Chicago Conference of The USA CBD Expo, October 28-30, 2021

October 18, 2021 12:53:11
The USA CBD Expo Chicago aims to be the greatest and largest CBD/hemp event in the country, bringing the most creative and best goods and brands to businesses and consumers on a constant basis, and compressing a rapidly growing industry into one all-encompassing, top event. This event is geared toward both newbies to the CBD sector and seasoned veterans. The conference will feature some of the industry’s top experts, who will deliver a variety of… Read More>> To know more about this event, visit https://usacbdexpo.com/chicago/. About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.  

The USA CBD Expo Will Be Back in Chicago In October, With More Than 50 Speakers and Hundreds of Brands Under One Roof

October 13, 2021 14:18:18
On October 28-30, 2021, Chicago’s McCormick Place will host the next USA CDB Expo. The nation’s largest CBD event series will continue with a three-day event in the Midwest that will provide industry enthusiasts with the opportunity to hear from more than 50 expert speakers, visit with hundreds of vendors, and network with thousands of their peers, following a successful return to an in-person format during its Atlanta-based conference in June. The October USA CBD Expo, which will be headlined by presenting sponsor 3Chi, the nation’s largest CBN and Delta-8 distributor, will be an early celebration of sorts, as the state of Illinois will soon mark the second anniversary of the legalization of… Read More>> To know more about the event, visit https://usacbdexpo.com/chicago/. About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

USA CBD Expo’s Chicago Conference Set to Take Place on October 28-30, 2021

October 11, 2021 13:34:28
  • USA CBD Expo will host their upcoming October conference at Chicago’s McCormick Place between October 28-30, 2021.
  • Forming part of the nation’s largest CBD event series, the USA CBD Expo will cater to CBD industry newcomers and seasoned industry professionals alike
  • The conference will play feature a series of keynote presentations and discussions delivered by some of the industry’s leading thinkers and innovators
  • In addition, the Expo will also be host to over 500 of the industry’s largest and most pioneering brands who will showcase their diverse product ranges under a single roof
USA CBD Expo is set to host their upcoming conference in conjunction with presenting sponsor, 3Chi, the nation’s largest CBN and Delta-8 distributor, at Chicago’s McCormick Place on October 28-30, 2021. The event will mark a new iteration of the nation’s largest CBD event series, which will provide conference attendees with the unique opportunity to hear from over 50 expert speakers, visit hundreds of vendors, and network alongside thousands of their peers. The USA CBD Expo has long established a well-earned reputation as the United States’ largest dedicated CBD conference series, bringing together the entire CBD and Hemp industry within a single, comprehensive, and all-inclusive event. Having originally started with an exclusive focus on… Read More>> Additional information about the USA CBD Expo, as well as details for registration, can be found at the USA CBD Expo website at https://usacbdexpo.com/ About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Poised to Become Global Leader in Manufacture of Rare Cannabinoids

October 8, 2021 10:40:54

InMed Pharmaceuticals (NASDAQ: INM) recently announced it had signed a definitive agreement to acquire 100% of BayMedica Inc., a U.S.-based private company specializing in the manufacture and commercialization of rare cannabinoids. InMed CEO Eric A. Adams described the acquisition as a transformative transaction for the company as it would give InMed a breadth of synthetic cannabinoid manufacturing capabilities. “BayMedica brings unparalleled cannabinoid manufacturing expertise in both chemical synthesis and biosynthesis together with industry veterans who have been pioneers in this space,” a recent article quotes Adams as saying. The article further notes that, once closed, the transaction will create a powerful combination. “It will make InMed a global leader in the manufacture of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches… At the same time, the combined company will continue to explore the therapeutic potential of cannabinoids and novel cannabinoid analogs for pharmaceutical drug development. It will also increase commercial sales of rare cannabinoids to the consumer health and wellness sector.”

To view the full article, visit https://cnw.fm/7rOGP

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (“CBN”), in diseases with high unmet medical need. The company is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based medicines. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Oral Drug Use Technology Nets Zacks Research Coverage

October 5, 2021 12:40:27
  • Zacks Small-Cap Research analysts recently announced coverage of Lexaria based on its market potential, valuing the company at $15 per share
  • Lexaria’s patented DehydraTECH(TM) technology is undergoing clinical and pre-clinical trials for potential use in treating hypertension, viral infections and other conditions that are currently being addressed through cannabidiol-based nutraceuticals or prescription drugs
  • Lexaria is also investigating alternatives to smoked or inhaled nicotine delivery to avoid lung harm, expanding the potential of its technology
  • DehydraTECH’s lymph system delivery method alternative to the digestive system provides more rapid bioavailability and fewer side effects, as well as the potential for better delivery across the blood-brain barrier
  • The relatively low-cost technology has the capacity to produce up to 400,000 consumer packaged goods though existing manufacturer relationships
Oral drug technology innovator Lexaria Bioscience (NASDAQ: LEXX) has drawn the attention of Zacks Small-Cap Research analysts, who have initiated coverage of Lexaria with a valuation of $15 per share because of the company’s patent portfolio supporting Lexaria’s patented DehydraTECH(TM) consumption technology and the multiple potential uses of the technology. DehydraTECH pairs active pharmaceutical ingredients (“APIs”) with select long-chain fatty acid (“LCFAs”) oils that serve as carriers for the APIs though the lymphatic system, converting these compounds into… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – The Alkaline Water Company Inc.’s (NASDAQ: WTER) (CSE: WTER) Alkaline88(R) and A88CBD(TM) to Exhibit at 2021 NACS Show

October 4, 2021 11:37:49

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER)the country’s largest independent alkaline water company, today announced that its subsidiaries, Alkaline88 and A88 Infused Products Inc., will be exhibitors at the 2021 NACS Show. The event is slated to take place from Oct. 6-8, 2021, at McCormick Place in Chicago, Illinois. According to the update, the A88CBD(TM) booth will be featuring the brand’s new line of six functional CBD waters powered by Vessl(R). “The 2021 NACS Show is a great opportunity for The Alkaline Water Company to showcase two strong brands. We’re looking forward to meeting buyers and sharing with them our Deliciously Smooth(TM) Alkaline88(R) and our six new A88CBD functional waters,” said Ricky Wright, president and CEO of The Alkaline Water Company. “Convenience stores sell billions of dollars’ worth of bottled water and they have been early adopters of CBD products. We’ve had outstanding growth in the convenience channel, and it remains a focus for us in fiscal year 2022.”

To view the full press release, visit https://cnw.fm/U1o26

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked Clean Beverage label. Quickly recognized as a growing lifestyle brand, Alkaline88 created the A88 Infused(TM) Beverage Division in 2018 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts as well as broad-spectrum hemp, powder packs, oil tinctures, capsules and gummies. To learn more about the company, please visit www.Alkaline88.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

USA CBD Expo 2021 Hosts the Nation’s Largest CBD and Hemp Trade Show

October 1, 2021 09:05:09
  • What: USA CBD Expo 2021
  • When: October 28-30, 2021
  • Where: Chicago, Illinois
  • Details on the Venue: Hosted at the famous McCormick Place convention center in downtown Chicago
  • Key Stats: 50+ field experts, 300 unique vendors, and thousands of high-quality products from all over the globe
The skyrocketing global CBD and hemp markets have only continued to dominate the industry after the COVID-19 pandemic. Now, professionals from around the world can finally come together to discuss the knowledge, experience and advice they’ve acquired this past year at the USA CBD Expo 2021 in Chicago, Illinois. The event is hosted from October 28-30 at the famous McCormick Place convention center and is considered the largest CBD expo series in the nation. The massive 2 billion dollar venue space and recent… Read More>> For further information about USA CBD Expo 2021 or to learn how to buy tickets, visit the event’s website at https://usacbdexpo.com About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Versatile DehydraTECH(TM) Technology Improving Taste, Bioabsorption, Efficacy of Drugs

September 30, 2021 10:50:20
  • Lexaria Bioscience is the global innovator behind the disruptive DehydraTECH(TM) drug delivery technology
  • DehydraTECH’s taste-masking capabilities eliminate the need for unwanted sweeteners or chemical masking agents
  • The technology also significantly increases the bioavailability of drugs, speeds up the rate of drug onset, and boosts brain absorption
  • DehydraTECH presents numerous opportunities and has been evaluated in R&D programs featuring DehydraTECH-processed nicotine, antivirals, and cannabidiol
Oral delivery is the easiest and most convenient way to administer medications, yet it is prevalently associated with patient noncompliance owing to many drugs’ bitter taste. The problem appears widespread and necessitating remedial bitterness-masking interventions. But as recently as 2013 (relative to the mid-19th century origin of the modern pharmaceutical industry), the taste-masking of oral solid dosage forms was still a major challenge that needed to be addressed by formulation or pharmaceutical scientists (https://cnw.fm/Wir6L). The most commonly used taste-masking methods at that time were film coating and the use of sweeteners, sugars, or flavors, but the latter is considered ineffective due to its inability to adequately mask the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Completes First Step in European Expansion Plan

September 27, 2021 11:56:47

Flora Growth Corp. (NASDAQ: FLGC) recently closed a €2 million investment in Hoshi International Inc., a fully integrated cannabis company, and uniquely positioned to become the leading provider of cannabis and derivative products for the budding European market. With the investment, Flora is set to capitalize on Hoshi’s strong European presence as well as leverage its technical know-how and understanding of its European market to not only expand its reach but also obtain its European Union Good Manufacturing Practices (“EU-GMP”) certification. A recent article reads, “Flora hopes to capitalize on Hoshi’s understanding of and presence within the European market to capitalize on its strategic growth plans. Closing this investment is a step in the right direction and a first in Flora’s overall expansion plan to venture into the European market for its cannabis products.”

To view the full article, visit https://cnw.fm/YBqfv

About Flora Growth Corp.

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enhancing Performance of Antiviral Drugs, CBD

September 24, 2021 13:52:12
Lexaria Bioscience Corp. (NASDAQ: LEXX) is making significant progress in advancing its patented DehydraTECH(TM) drug delivery technology. Lexaria recently reviewed its successful 2021 antiviral drug program. “The company has progressed significantly in evidencing that DehydraTECH can sufficiently enhance the usable fraction of known antiviral drugs that reach the bloodstream to safely and more effectively do what they are designed to accomplish,” reads a recent article. In addition to the antiviral program, Lexaria is also focused on another applied R&D program — hypertension. On July 29, it released partial results from a human clinical study, HYPER-H21-1, evaluating DehydraTECH-processed cannabidiol (“CBD”) for potential application against hypertension. “The study revealed a rapid and sustained drop in blood pressure with DehydraTECH-processed CBD and was most pronounced within the first 10 to 50 minutes of the study. This evidence reinforced the company’s pre-existing findings and further demonstrated its drug delivery technology offers superior performance over generic CBD controls.” To view the full article, visit https://cnw.fm/yKeZd About Lexaria Bioscience Corp. Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH(TM) improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted in nations with a combined population of 2.6 billion, and over 50 additional patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) Unveils New A88CBD(TM) Functional Waters

September 23, 2021 12:32:39

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER)the country’s largest independent alkaline water company, has launched a new line of A88CBD(TM) functional waters powered by Vessl(R). The new natural CBD functional waters have six options: Relax, Refresh, Rest, Reenergize, Relief and Resistance. The new offerings feature the patented Vessl closure technology, which is designed to provide fresher ingredients and flavor. The new brand, which represents a strategic move into the functional beverages space for WTER, will be sold under the company’s A88 Infused Products Division Inc. With the Vessl closure technology, the CBD and other active, functional ingredients are stored in a pressurized chamber in the bottle cap. The ingredients are released when the consumer twists the cap open, providing an instant infusion of fresh flavor and functionality. “The Alkaline Water Company is pleased to bring another product innovation to the market in the multibillion-dollar functional beverage category,” said The Alkaline Water Company CEO Ricky Wright in the press release. “Our current A88CBD Lemon Lime is having tremendous success in the marketplace, and our customers have asked us to expand into functionality, additional nonfunctional flavors and a nonflavored plain CBD alkaline water. Within the next 60 days we’ll have nine total A88CBD waters in the marketplace. . . . According to industry projections, the CBD beverage category alone will be over $1 billion by 2025, and A88CBD is first-to-market in the category with this amazing Vessl technology.”

To view the full press release, visit https://cnw.fm/tdq7h

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked Clean Beverage label. Quickly recognized as a growing lifestyle brand, Alkaline88 created the A88 Infused(TM) Beverage Division in 2018 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in six unique all-natural flavors, with new flavors coming soon. To learn more about the company, please visit www.Alkaline88.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Makes Early Leap into Expected Opening of Cannabis Trade in Panama

September 22, 2021 09:20:55
  • Flora Growth Corp., a cannabis company with low-cost cultivation and global distribution, recently reached a non-binding LOI with Panamanian importer and distributor Robust Farms Inc. to supply product from its portfolio
  • Panama is a country on the verge of opening to medical marijuana sales and the first in Central America to open a regulated market following legislation approved without a dissenting vote by the National Assembly
  • Flora Growth maintains a large licensed outdoor operation in Colombia, from which it cultivates cannabis that will be used in a variety of branded products
  • Flora Growth has been increasing its international outlets, including an agreement with Hoshi International Inc. expected to open up numerous opportunities in the European Union
On the heels of news that Panama’s National Assembly congress passed legislation legalizing medical marijuana (https://cnw.fm/3NzQt), internationally focused cannabis cultivator and brand builder Flora Growth (NASDAQ: FLGC) is generating excitement through the establishment of a non-binding LOI with Panamanian importer and distributor Robust Farms Inc. to supply its premium cannabidiol (“CBD”)-derivative products. Panamanian President Laurentino Cortizo is expected to sign the legislation despite a veto campaign from the conservative political opposition, which will make Panama the first Central American nation to… Read More>> NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Draws Closer to NDA Filing for DehydraTECH CBD

September 17, 2021 09:05:55
  • Lexaria just released the most important results yet from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure
  • Chris Bunka, Lexaria’s CEO, termed the results as “statistically significant”
  • Participants in the study reported up to an average 23% decrease in blood pressure and a 7% drop in systolic pressure
  • These results bring Lexaria closer to NDA filing with the FDA, making it a pioneer in CBD hypertension treatment
Lexaria Bioscience (NASDAQ: LEXX) just released the most recent results from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure (“BP”) over a 24-hour ambulatory period. The results, referred to as “Statistically significant” by Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria, inched the company closer to an eventual New Drug Application (“NDA”) (https://cnw.fm/KKLod). The study involved volunteers getting three doses of 150 mg of DehydraTECH CBD over 24 hours, spanning both sleep and wake cycles of activity. Participants coping with mild to moderate hypertension reported… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) Making Waves in E-Commerce

September 16, 2021 10:05:18

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), the country’s largest independent alkaline water company and The Clean Beverage Company(TM), has announced its entry into an agreement with a turnkey e-commerce agency that specializes in the management of digital marketplaces for major retailers including Amazon, Walmart.com and others. The company’s recently appointed Director of E-Commerce Chris Pitman will manage this new partnership. “We are making a stronger push than ever before into the e-commerce channel. As consumers continue to embrace digital shopping for groceries, e-commerce is a channel with significant upside potential for Alkaline88(R),” said Ricky Wright, president and CEO of The Alkaline Water Company. “We’ve continuously expanded our presence in the traditional grocery channel, and we will keep doing so, but the events of 2020 and 2021 have shown us definitively that online beverage buying habits are here to stay. eMarketer found that food and beverage was by far the fastest-growing e-commerce category in the U.S. in 2020 and forecasts 151.5 million U.S. digital grocery buyers by 2024 vs. 92.3 million in 2019.”

To view the full press release, visit https://cnw.fm/d1Yzd

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique, all-natural flavors with new flavors coming soon. In 2021, The Alkaline Water Company was pleased to welcome Shaquille O’Neal to its board of advisors and to serve as the celebrity brand ambassador for the Alklaine88 and A88 Infused brands. To purchase Alkaline88 and A88 Flavor Infused products online, visit www.Alkaline88.com. To learn more about the company, visit www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Great Strides Toward Filing IND Application for Patented DehydraTECH(TM) Technology

September 15, 2021 13:45:57
  • Lexaria has begun the formal process of preparing an application for Investigational New Drug status for DehydraTECH(TM) and cannabidiol for hypertension
  • The filing is being done with the assistance of an outside consultancy group, with Lexaria Bioscience designing non-clinical, clinical, and related product development required prior to the filing – all of which support Lexaria’s more ambitious goals
  • There have been two successful human hypertension trials done with the combination DehydraTECH-CBD therapy in 2021, following an original human clinical study in 2018, and many animal studies
  • Lexaria is making a strong case to support the efficacy of the technology for treating hypertension
Lexaria Bioscience (NASDAQ: LEXX), a global innovator currently enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs, is announcing that it has begun the formal process of preparing for Investigational New Drug (“IND”) certification with the US Food and Drug Administration (“FDA”). The IND will be for the company’s patented DehydraTECH-processed cannabidiol (“CBD”) as a prospective registered pharmaceutical treatment for high blood pressure (hypertension) (https://cnw.fm/gv5bN). With the help of an expert regulatory affairs and quality assurance consultancy group, Lexaria has begun preparations for a pre-IND meeting with the FDA and designing the non-clinical, clinical, and related product development IND-enabling work that must be completed prior to… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.